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ABSTRACT 
CLINICAL IMPLEMENTATION OF BREAST CANCER GENOMICS 
(Under the direction of Charles M. Perou) 
 
 
Genome-wide mRNA studies in breast cancer have revealed the heterogeneity of 
breast cancer and helped to characterize the distinct disease states.  The gene expression 
subtypes of breast cancer are associated with prognosis and response to therapy.  Thus, 
subtype diagnosis could influence care, but there exists no clinically available test for 
subtype assignment. Therefore, the goal of this research was to develop such an assay for 
biological discovery, and to asses its clinical utility. 
Clinical classification requires a measurement assay and accompanying 
quantitative model whose performance has been tested with relevant material using 
contemporary patient cohorts. A 50 gene qRT-PCR assay was developed using clinically 
available formalin-fixed paraffin-embedded materials, thus allowing utilization of 
existing archives.  An objective subtype assignment algorithm was simultaneously 
developed and assessed in a large cohort of patients who received no adjuvant systemic 
therapy.  The assay and algorithm demonstrated prognostic value in old age tissue 
providing proof of principal for further investigation. 
The first blinded evaluation used an ER-positive, tamoxifen treated cohort of 
archived specimens with up to 15 years of follow-up information.  Results of this study 
confirm strong association between subtype assignment and clinical outcomes. These 
associations validate the available information content, and confirm that the test is 
  


capable of identifying subjects for whom no further therapy is needed.  This identification 
is not currently possible, thus the assay demonstrates clear clinical utility in a 
contemporary cohort. 
The above studies demonstrate that gene expression-based assignments provide 
information regarding prognosis and therapeutic response.  DNA copy number 
aberrations (CNA) are also a likely data source of clinical and biological value, and thus, 
this additional information content was evaluated.  Results illustrate specific tumor DNA 
copy number aberrations hold prognostic value.  While these aberrations do not improve 
on gene expression based models, the CNA model explains similar prognostic variation 
in luminal tumors and thus may aid by identifying candidate drug targets in these tumors.  
Based on these studies we have developed a clinical assay for subtype diagnosis, 
demonstrated that the assay is more informative than clinical markers, and provide the 
first step toward elucidating tumorigenic pathways in luminal tumors. 
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CHAPTER 1 
INTRODUCTION 
 
Breast cancer is a heterogeneous disease with respect to molecular alterations, 
cellular composition, and clinical outcomes. The presence of ER and HER2 proteins as 
identify by immuno-histochemistry (IHC) generates four distinct categories.  ER status 
carries some prognostic information, with ER-positive tumors typically exhibiting better 
outcomes [1].  However, ER status and HER2 status are more valuable as treatment 
indicator,s with ER-positive tumors are more likely to be sensitive to tamoxifen [2], and 
HER2-positive tumors are typically more sensitive to trastuzamab [3].  This information 
has greatly improved the treatment of breast cancer [4], but much variation in prognosis 
and response to therapy is left unexplained by these four categories. 
Gene expression profiling by microarrays has given insight into the complexity of 
breast tumors and can be used to provide prognostic information beyond standard clinical 
assessments [5-9]. Specifically, the “intrinsic” subtypes luminal A (LumA), luminal B 
(LumB), HER2-enriched, basal-like, and normal-like have been extensively studied by 
microarray analysis [5,10-12]. These subtypes reflect the biology of the breast tumor and 
also predict clinical outcomes (Figure 1). It has been the basic goal of my thesis work to 
characterize the biological and clinical diversity of breast cancers using genomic 
approaches, and then to use this information to develop the next generation of possible 
clinical assays. 



 The biology of the intrinsic subtypes is complex, but lays the groundwork for the 
improved understanding of breast cancer patient outcomes. The LumA and LumB 
subtypes are typically estrogen receptor (ER) positive tumors and are identified by 
relatively high expression of the transcription factors ESR1, GATA3, FOXA1, and 
XBP1[12-15].  These two subtypes may also be distinguished by their expression of these 
genes, with LumB demonstrating lower expression relative to LumA.  However, cell 
cycle or proliferation associated genes more easily discriminate these two subtypes [16, 
17] where LumB tumors display higher expression of these genes, and higher 
proliferative activity, thus giving rise to more aggressive tumors.   
 The HER2-enriched subtype is named for its enrichment of tumors that contain 
amplification of the growth factor receptor ERBB2 (i.e. HER2). However, not all tumors 
in this class are ERBB2 amplified, and this class may generally represent luminal tumors 
which have lost cell cycle control governed by ESR1, with most of these tumors being 
HER2-amplified and ER-negative; it is thus likely that these tumors are instead governed 
by aberrant activity of growth factor signaling pathways [18], and they are likely 
sensitive to the anti-HER2 drug called trastuzumab. 
 The basal-like subtype is an aggressive subtype with high expression of 
proliferation genes and is often clinically labeled “triple negative” due to low, or no, 
expression of ESR1, PgR, and ERBB2.  Relative to other subtypes, basal-like tumors 
have limited treatment options, and patients typically experience poor outcomes [19, 30]. 
Basal-like tumors appear are more frequent in those of African-American [20, 21] and 
African [22] ancestry when compared to Caucasians.  Basal-like tumors harbor other 
genetic associations including a high frequency of DNA aberrations (i.e. significant 


chromosome instability) [23-25], tend to be TP53 mutant [10, 20], RB-deficient [26] and 
are associated with BRCA1 germline mutations [27].  Together these data suggest that 
the basal-like subtype is a profile of defective genetic repair pathways. 
A newly identified subtype is the Claudin-low group, which is a more recent 
discovery from an inter-species comparison of mouse mammary carcinomas versus 
human breast tumors [28]. This subtype is observed at much lower frequency than others 
(~5%) and is defined by the lack of expression of Claudins 3, 4 and 7, and E-cadherin. 
The general profile for these tumors is similar to murine mammary 
“spindloid/mesenchymal” tumors.  This subtype is currently being characterized [29] and 
appears to contain properties shared with stem cells (undifferentiated, low proliferation 
with mesenchymal features). 
 The last subtype is the normal-like group, which always contains the true normal 
breast samples and a few tumors. This classification in many cases is indicative of the 
presence of a significant amount of contaminating normal tissue [5], and thus this is not a 
true tumor subtype, but instead, is reflective of normal breast tissue. 
Subtype Identification and Clinical Relevance. The clinical information content of 
the gene expression subtypes has been repeatedly demonstrated. Luminal A tumors 
demonstrate the best prognosis of all subtypes [5,10-12], but also have poor response to 
standard chemotherapy [30].  The luminal A group accounts for the highest breast cancer 
mortality numerically, which represents about 40% of all breast cancer deaths [56].  
Luminal B tumors exhibit modestly higher response to chemotherapy, but their prognosis 
is much worse and targeted agents for this disease have not been identified.  The HER2-
enriched and basal-like groups also have poor prognosis in the absence of treatment, but 


display much better response to chemotherapy. Targeted treatment options are currently 
available for HER2-enriched patients (i.e. trastuzumab), and more are in various stages of 
development. 
The only biomarkers consistently used in clinical decisions are ER and HER2 
status. These biomarkers are correlated with the gene expression subtypes, but gene 
expression subtypes may provide more accurate information for both prognosis and 
prediction.  Thus, the assignment of subtype to a tumor could provide substantial 
information to a clinical case that is relevant for treatment decisions.  Subtype 
identification is also of great value in clinical trials where samples could be stratified.  
However, the lack of a clinically available test prevents this information from being 
accessible to oncologists.   
The gene expression subtypes were first identified with hierarchical clustering 
using fresh frozen tissue assayed on spotted cDNA microarrays[12].  This experiment 
was repeated with similar outcomes, but a number of limitations exist for clinical 
implementation.  A useful assay must be capable of testing clinically available samples 
such as formalin fixed, paraffin embedded (FFPE) tissues instead of fresh frozen tissues 
used for microarrays. An FFPE based test also has the potential to retrospectively stratify 
prior clinical trials.  A clinical test must have robust performance when presented with a 
single unknown sample, but hierarchical clustering is limited in this respect. A clinical 
test must provide clear indications, which limits the information of initial studies that 
used heterogeneously treated cohorts. Instead, the test must be run on large, well 
characterized, and population representative cohorts to provide well defined clinical 
indications.  


These requirements lead to the studies described in the following two chapters.  
The content of the assay and process for subtype assignment are developed in chapter 2 
along with initial evaluation in a large cohort of systemically untreated subjects. 
Quantitative RT-PCR is the gold standard for measuring relative gene expression in the 
clinic, and thus was chosen for the clinical assay development. The potential content was 
first optimized for utility in FFPE tissue up to 20 years old [31] so that stratification using 
archived clinical trial metarials would be possible. From this large pool, a reduced set 
was required for efficient testing of one sample on a clinical plate.  Generation of the 
content required identification of prototypical members of each subtype for training and 
robust gene selection.  A subtype classification algorithm was developed simultaneously 
with the selected content. Additional algorithms were developed to transform between 
and within subtype variation, along with clinical information, into prognostic 
classification of individual subjects. 
The novel 50 gene subtype classifier (PAM50) and risk classifiers were used to 
evaluate a collection of over 700 samples with no adjuvant systemic treatment. This 
validation set was made up of different microarray platforms and samples processed at 
different sites.  Thus, bioinformatics processing was required to minimize technical 
effects and construct homogeneous expression variables across the cohorts. A second 
cohort of homogeneously treated subjects was also evaluated to determine subtype 
sensitivity. The results of the development process and validation of subtype and risk 
classifiers are presented in chapter 2. 
The first large scale evaluation of the PAM50 assay in a treated cohort is 
presented in chapter 3.  Samples from this study included over 700 ER-positive subjects 

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homogeneously treated with tamoxifen. These samples were up to 15 year old FFPE 
tissue and thus also allowed validation that the assay was informative on archived studies.  
Complete clinical information allowed extensive comparison to currently available 
clinical factors, and novel prognostic models were evaluated.  Beyond validation of the 
assay, the clinically relevant goal of this study was to determine if a subset of patients 
could be identified where 5 years of tamoxifen was adequate treatment.  These results are 
presented in chapter 3. 
Information content of DNA. The PAM50 assay is one of many possible tests that 
use variation in gene expression to provide prognostic or predictive information. 
However, tumors are thought to arise from aberrations in genomic DNA that gives rise to 
variation in gene expression. Currently, little is known regarding DNA determinants of 
subtypes and the resulting clinical outcomes. However, with the exception of Claudin-
low, some genetic component has been identified in each subtype. For example, somatic 
TP53 mutation and germline BRCA1 mutations are associated with basal-like breast 
cancer [10,20], ERBB2/HER2 amplification is common in the HER2-enriched subtype 
[12], and recent population based findings such as FGFR2 are likely predisposing to 
luminal tumors [32-34]. These genetic events may describe a significant proportion of 
variation in the transcriptome. In addition, other genetic aberrations may mimic these 
known events and generate similar expression phenotypes that define the subtypes.  
The subtype specific DNA associations may be causative, as some tumor genomic 
DNA losses are known cancer causing events, like loss of the TP53 and/or RB1 tumor 
suppressor genes [35,36]. Given the subtype associations and causative nature of DNA, it 
is likely that the objective identification of these potential tumor causing events, and their 
	

inclusion into our current predictive models, could increase the accuracy of these models. 
Therefore in chapter 4 the potential tumor generating events are identified, prognostic 
and predictive abilities of CNA based models are evaluated, and compared to our current 
gene expression and clinical models of prognosis. 
Construction of successful models provides two opportunities for determining the 
clinical implications of tumor DNA.  The tumor DNA may harbor variation that is 
prognostic, but concordant with current clinical and expression based classifications. A 
second possibility is that variation in tumor DNA describes prognostic variation not 
otherwise explained by expression or other clinical parameters. Here the predictive ability 
of the novel locus will be evaluated in detail to understand the context in which it is 
informative 
Successful studies using tumor DNA have been reported in breast cancer [37-43].  
These studies use array based comparative genomic hybridization (aCGH), which is one 
assay that measures genome-wide genetic variation. aCGH uses microarrays to identify 
copy number aberrations (CNA) in tumor genomic DNA, which can detect both gains 
and losses of DNA. aCGH relies on the relative difference in hybridization intensity 
between experimental sample DNA and reference DNA [41].  SNP based genotyping 
arrays are now available that also allow for the detection of  hybridization intensity in an 
allele specific fashion [44] and with a higher density of measurement. These technologies 
have matured such that multiple large studies have been performed, and the resulting 
DNA measures and clinical correlates made available.  A large cohort of this type can be 
used to train and test prognostic models of DNA, and thus permitted the study presented 
in chapter 4. 


These published studies of copy number aberrations (CNAs) are challenging to 
combine due to the diversity of genomic platforms/assays involved.  Other problems such 
as "genomic waves" [45-47], contaminating normal [48, 49], and anueploidy [50, 51] 
complicate estimation of individual copy number and identification of CNA regions. This 
first attempt at model building with CNAs will rely on segment identification performed 
in larger or more focused studies [52,53], and will consider all copy number estimates as 
relative values.  The previously defined segments [54,55] will provide a mapping of 
different platforms to a universal feature set while also allowing broader inference from 
any identified segments. This strategy will also provide substantial dimension reduction 
(10-100x) due to the summarization across only known regions of CNAs.  Rigorous 
testing of any model is required to ensure the model is not sensitive to effects only 
present in the training set, and is robust to all aspects of data collection and processing. 
 The experiments in chapters 2 and 3 describe the development and evaluation of a 
clinically relevant prognostic model of gene expression subtypes. The 1400+ samples in 
these studies provide robust evaluation for prognostic models of gene expression. A 
model of CNAs has the potential to add new information to the gene expression model, or 
may recapitulate the gene expression information, but reveal aberrations causative of 
prognosis.  The experiments described in chapter 4 make use of over 1100 DNA samples 
to evaluate the prognostic ability of CNAs.  If successful, this should add to the gene 
expression studies of breast cancer in chapters 2 and 3, and promote the same clinical 
development cycle with DNA assays.  If successful, these studies should increase our 
knowledge of specific genetic factors that contribute to breast tumorigenesis and improve 
outcome predictions.  

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FIGURES 
  
 
 
 
 
 
 
Figure 1.  Hierarchical clustering of human breast tumors.  (A) Breast tumor samples 
(n=677) clustered using the 1300 intrinsic gene list (Hu et al., 2006).  Clustering 
identifies the five major intrinsic subtypes;  Luminal A = dark blue (subgroup: A’ = 
brown), Luminal B = light blue, Normal-like = green, Basal-like = red, HER2+/ER- = 
pink.  Genes with high expression levels unique to each subtype are labeled on the right.  
(B) Kaplan- Meier survival analyses across subtypes. RFS: relapse-free survival, OS: 
overall survival. 
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CHAPTER 2 
SUPERVISED RISK PREDICTOR OF BREAST CANCER BASED ON INTRINSIC 
SUBTYPES 
 
Purpose: To improve on current standards for breast cancer prognosis and 
prediction of chemotherapy benefit by developing a risk model that incorporates the gene 
expression–based “intrinsic” subtypes luminal A, luminal B, HER2-enriched, and basal-
like.  
Methods: A 50-gene subtype predictor was developed using microarray and 
quantitative reverse transcriptase polymerase chain reaction data from 189 prototype 
samples. Test sets from 761 patients (no systemic therapy) were evaluated for prognosis, 
and 133 patients were evaluated for prediction of pathologic complete response (pCR) to 
a taxane and anthracycline regimen. 
Results: The intrinsic subtypes as discrete entities showed prognostic significance 
and remained significant in multivariable analyses that incorporated standard parameters 
(estrogen receptor status, histologic grade, tumor size, and node status). A prognostic 
model for node-negative breast cancer was built using intrinsic subtype and clinical 
information. The C-index estimate for the combined model (subtype and tumor size) was 
a significant improvement on either the clinicopathologic model or subtype model alone. 
The intrinsic subtype model also predicted neoadjuvant chemotherapy efficacy with a 
negative predictive value for pCR of 97%. 

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Conclusion: Diagnosis by intrinsic subtype adds significant prognostic and 
predictive information to standard parameters for patients with breast cancer. The 
prognostic properties of the continuous risk score will be of value for the management of 
node-negative breast cancers. The subtypes and risk score can also be used to assess the 
likelihood of efficacy from neoadjuvant chemotherapy. 
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INTRODUCTION 
Breast cancer is a heterogeneous disease with respect to molecular alterations, 
cellular composition, and clinical outcome. This diversity creates a challenge in 
developing tumor classifications that are clinically useful with respect to prognosis or 
prediction. Gene expression profiling by microarray has given us insight into the 
complexity of breast tumors and can be used to provide prognostic information beyond 
standard clinical assessment.[1-7] For example, the 21-gene Oncotype Dx assay can be 
used to risk stratify early-stage estrogen receptor (ER) –positive breast cancer.[4,5] 
Another strong predictor of outcome in ER-positive disease is proliferation or genomic 
grade.[7-9] In addition, the 70-gene MammaPrint microarray assay has shown prognostic 
significance in ER-positive and ER-negative early-stage node-negative breast 
cancer.[2,3] 
 The “intrinsic” subtypes luminal A (LumA), luminal B (LumB), HER2-enriched, 
basal-like, and normal-like have been extensively studied by microarray and hierarchical 
clustering analysis.[1,6,10-12] Here, we study the utility of these subtypes alone and as 
part of a risk of relapse predictor in two cohorts: (1) patients receiving no adjuvant 
systemic therapy, and (2) patients undergoing paclitaxel, fluorouracil, doxorubicin, and 
cyclophosphamide (T/FAC) neoadjuvant chemotherapy. The risk of relapse models were 
compared with standard models using pathologic stage, grade, and routine biomarker 
status (ER and HER2). 
METHODS 
Samples and Clinical Data. Patient cohorts for training and test sets consisted of 
samples with data already in the public domain [7,13-16] and fresh frozen and formalin-

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fixed paraffin-embedded (FFPE) tissues collected under institutional review board– 
approved protocols at the University of British Columbia (Vancouver, British Columbia, 
Canada), University of North Carolina (Chapel Hill, NC), Thomas Jefferson University 
(Philadelphia, PA), Washington University (St Louis, MO), and the University of Utah 
(Salt Lake City, UT). The training set for subtype prediction consisted of 189 breast 
tumor samples and 29 normal samples from heterogeneously treated patients given the 
standard of care dictated by their histology, stage, and clinical molecular marker status. 
The risk of relapse (ROR) models for prognosis in untreated patients were trained using 
the node-negative, untreated cohort of the Netherlands Cancer Institute data set (n= 
141).[13] The subtype prediction and ROR models were independently tested for 
prognosis [7,14,15] and chemotherapy response. The Hess et al data set [16] used for 
prediction of chemotherapy sensitivity was not associated with long-term outcome data 
and was evaluated based on information for pathologic complete response (pCR). 
Clinical characteristics of the microarray training and test sets are presented in Table 1. 
[17]  
Nucleic Acid Extraction. Total RNA was purified from fresh-frozen samples for 
microarray using the Qiagen RNeasy Midi Kit according to the manufacturer’s protocol 
(Qiagen, Valencia, CA). The integrity of the RNA was determined using an Agilent 2100 
Bioanalyzer (Agilent Technologies, Palo Alto, CA). The High Pure RNA Paraffin Kit 
(Roche Applied Science, Indianapolis, IN) was used to extract RNA from FFPE tissues 
(2-10 mm sections or 1.5-mm punches) for quantitative reverse transcriptase polymerase 
chain reaction (qRT-PCR). Contaminating DNA was removed using Turbo DNase 
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(Ambion, Austin, TX). The yield of total RNA was assessed using the NanoDrop ND-
1000 Spectrophotometer (NanoDrop Technologies Inc, Rockland, DE).  
Reverse Transcription and qRT-PCR First-strand cDNA was synthesized using 
Superscript III reverse transcriptase (first Strand Kit; Invitrogen, Carlsbad, CA) and a 
mixture of random hexamers and gene-specific primers. PCR amplification and 
fluorescent melting curve analysis was done on the LightCycler 480 using SYBR Green I 
Master Mix (Roche Applied Science). 
Microarray Total RNA isolation, labeling, and hybridizations on Agilent human 
1Av2 microarrays or custom-designed Agilent human 22k arrays were performed using 
the protocol described in Hu et al.[6] All microarray data have been deposited into the 
Gene Expression Omnibus [18] under the accession number of GSE10886.  
Identification of Prototypical Intrinsic Subtype Samples and Genes. To develop a 
clinical test that could make an intrinsic subtype diagnosis, we used a method to 
objectively select prototype samples for training and then predicted subtypes independent 
of clustering. To identify prototypic tumor samples, we started with an expanded 
“intrinsic” gene set comprised of genes found in four previous microarray 
studies.[1,6,8,11] The normal-like class was represented using true “normals” from 
reduction mammoplasty or grossly uninvolved tissue, thus we have removed the normal-
like class from all outcome analyses and consider this classification as a quality-control 
measure. A total of 189 breast tumors across 1,906 “intrinsic” genes were analyzed by 
hierarchical clustering (median centered by feature/gene, Pearson correlation, average 
linkage), [19] and the sample dendrogram was analyzed using “SigClust”.[20]  A total of 
122 breast cancers from 189 individuals profiled by qRT-PCR and microarray had 
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significant clusters representing the “intrinsic” subtypes luminal A (LumA), luminal B 
(LumB), HER2-enriched, basal-like, and normal-like (Fig 1). Four additional groups 
were identified in the training set as significantly reproducible clusters. All four of these 
groups have similar expression profiles as the luminal tumors and could represent 
intermediate states or tissue heterogeneity.  
Gene Set Reduction Using Prototype Samples and qRT-PCR. A minimized gene 
set was derived from the prototypic samples using the qRT-PCR data for 161 genes that 
passed FFPE performance criteria established in Mullins et al.[21] Several minimization 
methods were used, including top “N” t test statistics for each group,[22] top cluster 
index scores,[23] and the remaining genes after “shrinkage” of modified t test 
statistics.[24] Cross-validation (CV) (random 10% left out in each of 50 cycles) was used 
to assess the robustness of the minimized gene sets. The “N” t test method was chosen 
due to having the lowest CV error. The 50 genes selected and their contribution to 
distinguishing the different subtypes is provided in Figure 2.  
Sample Subtype Prediction. The 50 gene set was compared for reproducibility of 
classification across three centroid-based prediction methods: Prediction Analysis of 
Microarray (PAM),[24] a simple nearest centroid,[6] and Classification of Nearest 
Centroid.[25] In all cases, the subtype classification is assigned based on the nearest of 
the five centroids. Because of its reproducibility in subtype classification, the final 
algorithm consisted of centroids constructed as described for the PAM algorithm [24] and 
distances calculated using Spearman’s rank correlation. The centroids of the training set 
using the 50-gene classifier (henceforth called PAM50) are shown in Figure 3.  
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Prognostic and Predictive Models Using Clinical and Molecular Subtype Data. 
Univariate and multivariable analyses were used to determine the significance of the 
intrinsic subtypes (LumA, LumB, HER2-enriched, and basal-like) in untreated patients 
and in patients receiving neoadjuvant chemotherapy. For prognosis, subtypes were 
compared with standard clinical variables (tumor size [T], node status [N], ER status, and 
histologic grade), with time to relapse (ie, any event) as the end point. Subtypes were 
compared with grade and molecular markers (ER, progesterone receptor [PR], HER2) for 
prediction in the neoadjuvant setting because pathologic staging is not applicable. 
Likelihood ratio tests were done to compare models of available clinical data, subtype 
data, and combined clinical and molecular variables. Categoric survival analyses were 
performed using a log-rank test and visualized with Kaplan-Meier plots. 
Developing Risk Models With Clinical and Molecular Data. The subtype risk 
model was trained with a multivariable Cox model using Ridge regression fit to the node-
negative, untreated subset of the van de Vijver cohort.13ARORscore was assigned to 
each test case using correlation to the subtype alone (1) (ROR-S) or using subtype 
correlation along with tumor size (2) (ROR-C):  
ROR-S  = 0.05*basal+0.12*HER2+0.34*LumA+0.23*LumB  (1)  
ROR-C = 0.05*basal+0.11*HER2+0.23*LumA+0.09*LumB+0.17*T  (2)  
The sum of the coefficients from the Cox model is the ROR score for each 
patient. To classify samples into specific risk groups, we chose thresholds from the 
training set that required no LumA sample to be in the high-risk group and no basal-like 
sample to be in the low-risk group. Thresholds were determined from the training set and 
remained unchanged when evaluating test cases. SiZer analysis was performed to 
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characterize the relationship between theROR score and relapse-free survival [26] (Fig 
5). The 95% CIs for the ROR score are local versions of binomial CIs, with the local 
sample size computed from a Gaussian kernel density estimator based on the Sheather- 
Jones choice of window width.[27] 
Comparison of Relapse Prediction Models. Four models were compared for 
prediction of relapse: (1) a model of clinical variables alone (tumor size, grade, and ER 
status), (2) ROR-S, (3) ROR-C, and (4) a model combining subtype, tumor size, and 
grade. The C-index [28] was chosen to compare the strength of the various models. For 
each model, the C-index was estimated from 100 randomizations of the untreated cohort 
into two thirds training set and one thirds test set. The C-index was calculated for each 
test set to form the estimate of each model, and C-index estimates were compared across 
models using the two sample t test.  
DISTRIBTUTION OF INTRINSIC SUBTYPES IN COMPARISON WITH CLINICAL 
MARKER STATUS 
Of the 626 ER-positive tumors analyzed in the microarray test set (Table 1), 73% 
were luminal (A or B), 11% were HER2-enriched, 5% were basal-like, and 12% were 
normal-like. Conversely, the ER-negative tumors comprised 11% luminal, 32% HER2-
enriched, 50% basal-like, and 7% normal-like. The neoadjuvant study from Hess et al 
[16] provided an opportunity to analyze the subtype distribution across clinical HER2 
(HER2clin) status. Sixty-four percent (21 of 33) of HER2clin-positive were classified as 
HER2-enriched by gene expression. Only two (6%) of 33 HER2clin-positive tumors were 
classified as basal-like. Although the majority of the HER2clin-negative tumors were 
luminal (56%), 9% were classified as HER2-enriched and 24% were basal-like. Thus 
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although the subtype diagnoses have markedly different distributions depending on ER or 
HER2 status, all subtypes were represented in ER-positive, ER-negative, HER2- positive, 
and HER2-negative categories. This finding demonstrates that ER and HER2 status alone 
are not accurate surrogates for true intrinsic subtype status. The intrinsic subtypes showed 
a significant impact on prognosis for relapse-free survival in untreated (no systemic 
therapy) patients and when stratified by ER status (Fig 4).  
RISK OF REPLAPSE MODELS FOR PROGNOSIS IN NODE-NEGATIVE BREAST 
CANCER 
Cox models were tested using intrinsic subtype alone and together with clinical 
variables. Table 2 shows the multivariable analyses of these models in an independent 
cohort of untreated patients. [7,13-15] In model A, subtypes, tumor size (T1 v greater), 
and histologic grade were found to be significant factors for ROR. The great majority of 
basal-like tumors (95.9%) were found to be medium or high grade, and therefore, in 
model B, which is an analysis without grade, basal-like becomes significant. Model C 
shows the significance of the subtypes in the node-negative population. All models that 
included subtype and clinical variables were significantly better than either clinical alone 
(P < 0.0001) or subtype alone (P < 0.0001).  
We trained a relapse classifier to predict outcomes within the context of the 
intrinsic subtypes and clinical variables. A node-negative, no systemic treatment cohort 
(n=141) was selected from the van de Vijver microarray data set [13] to train the ROR 
model and to select cut-offs (Fig 5). Figure 6 provides a comparison of the different 
models using the C-index. There is a clear improvement in prediction with subtype 
(ROR-S) relative to the model of available clinical variables only (Fig 6A). A 
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combination of clinical variables and subtype (ROR-C) is also a significant improvement 
over either individual predictor. However, information on grade did not significantly 
improve the C-index in the combined model, indicating that the prognostic value of grade 
had been superseded by information provided by the intrinsic subtype model.  
Figure 6 also presents the use of the ROR-C prognostic model for ROR in a test 
set of untreated node-negative patients. As was seen on the training data set, only the 
LumA group contained any low-risk patients (Fig 6B), and the three-class distinction of 
low, medium, and high risk was prognostic (Fig 6C). Lastly, Figure 6D shows that the 
ROR-C scores have a linear relationship with probability of relapse at 5 years.  
SUBTYPES AND PREDICTION OF RESPONSE TO NEOADJUVANT T/FAC 
TREATMENT 
 The Hess et al [16] study that performed microarray on tumors from patients 
treated with T/FAC allowed us to investigate the relationship between the subtypes and 
clinical markers and how each relates to pCR. Table 3 shows the multivariable analyses 
of the subtypes together with clinical molecular markers (ER, PR, HER2) and either with 
(model A) or without (model B) histologic grade. The only significant variables in the 
context of this study were the intrinsic subtypes. We found 94% sensitivity and 97% 
negative predictive value for identifying non-responders to chemotherapy when using the 
ROR-S model to predict pCR (Fig 7A). The relationship between high-risk scores and a 
higher probability of pCR (Fig 7B) is consistent with the conclusion that indolent ER-
positive tumors (LumA) are less responsive to chemotherapy. However, unlike ROR for 
prognosis, a plateau seems to be reached for the ROR versus probability of pCR, 
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confirming the presence of significant chemotherapy resistance among the highest risk 
tumors.  
SUBTYPE PREDICTION AND OUTCOME ON FFPE SAMPLES USING qRT-PCR  
The subtype classifier and risk predictor were further validated using a 
heterogeneously treated cohort of 279 patients with FFPE samples archived between 
1976 and 1995. The subtype classifications followed the same survival trends as seen in 
the microarray data, and the ROR score was significant for long-term relapse predictions 
(Fig 8A, online only). This old-age sample set was also scored for standard clinical 
markers (ER and HER2) by immunohistochemistry (IHC) and compared with the gene 
expression–based test. Analysis of ESR1 and ERBB2 by gene expression showed high 
sensitivity and specificity as compared with the IHC assay (Figs 8B and 8C). The 
advantages of using qRT-PCR versus IHC are that it is less subjective than visual 
interpretation and it is quantitative.  
DISCUSSION  
There have been numerous studies that have analyzed interactions between breast 
cancer intrinsic subtypes and prognosis,[1,6,11] genetic alterations,[29] and drug 
response.[30] Because of the potential clinical value of subtype distinctions, we 
developed a standardized method of classification using a statistically derived gene and 
sample set that we have validated across multiple cohorts and platforms. The large and 
diverse test sets allowed us to evaluate the performance of the PAM50 assay at a 
population level and in relation to standard molecular markers. An important finding 
from these analyses is that all of the intrinsic subtypes are present and clinically 
significant in terms of outcome predictions in cohorts of patients diagnosed with either 



ER-positive or ER-negative tumors (Fig 1). Thus the molecular subtypes are not simply 
another method of classification that reflects ER status.  
Stratification of the subtypes within HER2clin-positive samples did not show 
significance in outcome predictions; however, there were fewer numbers and less follow-
up in this category. Nevertheless, there was clear separation of the curves for those 
HER2clin-positive patients classified as HER2-enriched (worse prognosis) compared 
with those with luminal subtypes (better prognosis). We found that 6% of HER2clin-
positive tumors were classified as basal-like. It has been suggested that HER2clin-
positive tumors expressing basal markers may have worse outcome when given a 
chemotherapeutic regimen of trastuzumab and vinorelbine.[31] 
Approximately one third of the HER2-enriched expression subtype were not 
HER2clin-positive tumors, suggesting the presence of an ER-negative, non-basal subtype 
that is not driven by HER2 gene amplification. The prototype samples selected to 
represent the HER2- enriched group had high expression of the 17q12-21 amplicon genes 
(HER2/ERBB2 and GRB7), FGFR4 (5q35), TMEM45B (11q24), and GPR160 (3q26). In 
addition, other growth factor receptors such as epidermal growth factor receptor are 
included within the PAM50 and could potentially also contribute to the HER2-enriched 
genomic classification.  
We found that approximately 10% of breast cancers were classified as normal-
like and can be either ER-positive or ER-negative and have an intermediate prognosis. 
Because the normal-like classification was developed by training on normal breast tissue, 
we suspect that the normal-like class is mainly an artifact of having a high percentage of 
normal “contamination” in the tumor specimen. Other explanations include a group of 
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slow-growing basal-like tumors that lack expression of the proliferation genes or a 
potential new subtype that has been referred to as claudin-low tumors.[32] Detailed 
histologic, immunohistochemical, and additional gene expression analyses of these cases 
are needed to resolve these issues. Because of the uncertainties, however, the normal-like 
samples were removed when modeling ROR.  
The multivariable analysis for prognosis (ie, no systemic treatment) suggested 
that the best model was to use subtype with pathologic staging. Because pathologic 
staging is not available at diagnosis in the neoadjuvant setting, we used histologic grade 
and clinical biomarkers as the standard for prediction of chemotherapy response before 
resection. In this context, only the subtypes LumB and basal-like were predictive in the 
multivariable analysis that included histologic grade, ER, PR, and HER2 status (note that 
the Hess et al16 study did not incorporate trastuzumab into the regimen). The ROR score 
from the subtype-alone model was also the most predictive of neoadjuvant response. One 
of the major benefits of the ROR predictor is the identification of patients in the LumA 
group who are at a low ROR on the basis of pure prognosis and for whom the benefit 
from neoadjuvant therapy is unlikely. Thus the ROR predictor based on subtypes 
provides similar information as the Oncotype Dx Recurrence Score for patients with ER-
positive, node-negative disease.[4,5] Furthermore, the PAM50 assay provides a ROR 
score for all patients, including those with ER-negative disease, and is highly predictive 
of neoadjuvant response when considering all patients.  
In summary, the intrinsic subtype and risk predictors based on the PAM50 gene 
set added significant prognostic and predictive value to pathologic staging, histologic 
grade, and standard clinical molecular markers. The qRT-PCR assay can be performed 
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using archived breast tissues, which will be useful for retrospective studies and 
prospective clinical trials. 
  



ACKNOWLEDGEMENTS 
The manuscript presented in this chapter was reproduced in part with written 
permission from the Journal of Clinical Oncology. I would like to thank the following 
scientists for their collaborative help on this project:  
Conception and design: Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. 
Bernard 
Administrative support: John F. Quackenbush 
Provision of study materials or patients: Juan Palazzo, Torsten O. Nielsen, Matthew J. 
Ellis, Charles M. Perou, Philip S. Bernard 
Collection and assembly of data: Michael Mullins, Maggie C.U. Cheang, Samuel Leung, 
David Voduc, Tammi Vickery, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan 
Hu, John F. Quackenbush, Inge J. Stijleman, Juan Palazzo, J.S. Marron, Andrew B. 
Nobel, Elaine Mardis, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. 
Bernard 
Data analysis and interpretation: Michael Mullins, Maggie C.U. Cheang, Samuel Leung, 
David Voduc, Sherri Davies, Christiane Fauron, Xiaping He, Zhiyuan Hu, J.S. Marron, 
Andrew B. Nobel, Torsten O. Nielsen, Matthew J. Ellis, Charles M. Perou, Philip S. 
Bernard 
Manuscript writing: David Voduc, Torsten O. Nielsen, Matthew J. Ellis, Charles M. 
Perou, Philip S. Bernard  


TABLES 
 
 
 



 !

 "
 	 
  #
$%& $%& 
$%&
$   

& 		  
$   
&  	 
$ #  
& # 
 
'(
   
)
   

*+ 
  

,  
 
- 
	 
 	
*.# 
 
 	
*./ 
  
	
-01
&  
 

/.&.2  
 
	
.&.2 
 	 
"-.34

! .56.34
7*.34
	78
.34

79.34
7
:; 
01

-01


:<
=
,#
;.3>..>;>
>
: .
,1. 
?:.@A


 
 
 
 
  
,.
8;. -<1  &. -<1  &. -<1  &.
/.&.2! 3 3   3 3
-01
&!    	  	
*./! 
 	  	 
 	
01:B 3 3 3 3 3 3

:<C  
 
   
:D    
  
-.=" 
 
    
?..:; E 	 	 	
?..>..F 	 	 	
!*.#.5.
B-<501 2
C:<'(
)

D# G
"=.;.+..
E:5 &.  .; .
F:5 &.  ....
	


# / >
,.
8;. H1  &. H1  &.
/.&.2!    
-01
&! 3 3 3 3	
*/! 
  
 
01:B &3
 3 &3 3

-01
:B 3 3
 3 3

I1:B &3 3
 &3 3
-.=" 3
 3 & &
?..:; C 3	 3
?..>..D  
!*.#.5.
B-<5014I14-01
 2
C:ﬁ &.   G.G ;  .
D:ﬁ &.   G.G. .   .
"=. ;.+..
# /
	







FIGURES 
 
 
 
Fig 1. Hierarchical clustering and SigClust analysis of microarray data using 1,906 
“intrinsic” genes and 189 samples. The SigClust algorithm statistically identifies 
significant/unique groups by testing the null hypothesis that a group of samples is from a 
single cluster, where a cluster is characterized as a multivariable normal 
distribution. SigClust was run at each node of the dendrogram beginning at the root and 
stopping when the test was no longer significant (P < 0.001). Statistical selection 
using SigClust identified nine significant groups, including the previously identified 
subtypes designated as luminal A (dark blue), luminal B (light blue), HER2-enriched 
(pink), normal-like (green), and basal-like (red). 
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Fig 2. Focused heatmap of Classification by Nearest Centroids (ClaNC) selected genes 
for each subtype. The ClaNC algorithm was optimized to select 10 genes 
per class for a total of 50 genes. The 10 genes for each class are shown as red/green 
according to their expression in a class. Black indicates that gene was not selected 
for the given class. 
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Fig 3. Heatmap of the centroid models of subtype. The centroids were constructed using 
the Classification by Nearest Centroids selected genes and calculated as 
described for the Prediction Analysis of Microarray algorithm. The expression values are 
shown as red/green according to their relative expression level. 
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Fig 4. PAM50 intrinsic subtype prognosis for relapse-free survival (RFS). (A) Outcome 
predictions according to the four tumor subtypes in a test set of 710 
node-negative, no systemic adjuvant therapy patients. (B) Outcome by subtype in the 
subset of patients with estrogen receptor (ER) –positive disease from Figure 1A. 
(C) Outcome by subtype in patients with ER-negative disease. (D) Outcome by subtype 
in HER2clin-positive patients. 
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Fig 5. Developing a continuous risk score based on subtypes and clinical variables. (A) A 
family of smoothing functions illustrates the general linear relationship
between the risk of relapse (ROR) score and relapse
Significance of the slopes in the smoothed lines is plotted for each bandwidth across
the range of scores. Blue indicates a significant positive slope, purple indicates 
nonsignificant slope, and green indicates too few data for inference.
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-free survival at 5 years. (B) 
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Fig 6. Risk of relapse (ROR) predictions using a test set of node
therapy patients. (A) C-index analyses of four different Cox models using a
test set of node-negative, untreated patients. (B) ROR
scores stratified by subtype. (C) Kaplan
points determined in training. (D) Analysis of the ROR
survival shows a linear relationship (with the dashed lines showing the 95% CIs).
ER, estrogen receptor; RFS, relap
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-C (tumor size and subtype model) 
-Meier plots of the test set using cut
-C model versus probability of 
se-free survival. 
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Fig 7. Relationship between risk of relapse (ROR) score and paclitaxel, fluorouracil, 
doxorubicin, and cyclophosphamide neoadjuvant response. (A) Receiver operating
characteristic curve analysis of ROR
response (pCR) in the Hess et al16 test set. (B) ROR
of pCR. PPV, positive predictive value; NPV, negative predictive value; AUC, area under 
the curve. 
 
 
Fig 8. Analysis of an old-aged formalin
combined risk of relapse (ROR)
risk of relapse in 279 patients from the University of British Columbia. (B) Receiver 
operating characteristic curve analysis of quantitative 
polymerase chain reaction (qRT
(IHC) data. (C) Receiver operating characteristic curve analysis for qRT
HER2/ERBB2 versus HER2clin
PPV, positive predictive value; NPV, negative predictive value; AUC, area under
the curve. 
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-PCR) data for ESR1 versus immunohistochemistry 
-positive (IHC and/or fluorescent in situ hy
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CHAPTER 3 
A COMPARISON OF PAM50 INTRINSIC SUBTYPING WITH 
IMMUNOHISTOCHEMISTRY AND CLINICAL PROGNOSTIC FACTORS IN 
TAMOXIFEN-TREATED ESTROGEN RECEPTOR POSITIVE BREAST CANCER 
 
Purpose: To compare clinical, immunohistochemical and gene expression models 
of prognosis applicable to formalin-fixed, paraffin-embedded blocks in a large series of 
estrogen receptor positive breast cancers, from patients uniformly treated with adjuvant 
tamoxifen. 
Methods: qRT-PCR assays for 50 genes identifying intrinsic breast cancer 
subtypes were completed on 786 specimens linked to clinical (median follow-up 11.7 
years) and immunohistochemical (ER, PR, HER2, Ki67) data. Performance of predefined 
intrinsic subtype and Risk-Of-Relapse scores was assessed using multivariable Cox 
models and Kaplan-Meier analysis. Harrell’s C-index was used to compare fixed models 
trained in independent data sets, including proliferation signatures. 
Results: Despite clinical ER positivity, 10% of cases were assigned to non-
Luminal subtypes. qRT-PCR signatures for proliferation genes gave more prognostic 
information than clinical assays for hormone receptors or Ki67. In Cox models 
incorporating standard prognostic variables, hazard ratios for breast cancer disease 
specific survival over the first 5 years of follow-up, relative to the most common Luminal 

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A subtype, were 1.99 (95% CI: 1.09-3.64) for Luminal B, 3.65 (1.64-8.16) for HER2-
enriched and 17.71 (1.71-183.33) for the basal-like subtype. For node-negative disease, 
PAM50 qRT-PCR based risk assignment weighted for tumor size and proliferation 
identifies a group with >95% 10 yr survival without chemotherapy. In node positive 
disease, PAM50-based prognostic models were also superior to current clinical variables. 
Conclusion: The PAM50 gene expression test for intrinsic biological subtype can 
be applied to large series of formalin-fixed paraffin-embedded breast cancers, and gives 
more prognostic information than clinical factors and immunohistochemistry using 
standard cut points. 
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INTRODUCTION 
A number of gene expression technologies and statistical models have reported 
methodologies to identify breast cancer patients with estrogen receptor positive, node 
negative (N0) disease that may be adequately managed with five years of tamoxifen 
monotherapy [1-5]. However, these studies often included patients with tumors already 
associated with established low risk biomarkers, for example low grade histology, low 
Ki67 based proliferation index and favorable surgical stage. It therefore remains 
controversial whether genomic assays should be applied routinely, or whether surgical 
stage and a limited number of immunohistochemical markers will, in most cases, be 
adequate and less costly [6].  
The clinical significance of continued efforts in this area is relevant for decisions 
regarding both chemotherapy and endocrine agents, as patients at low risk after five years 
of tamoxifen monotherapy could be spared the morbidity associated with extended 
aromatase inhibitor therapy [7]. Studies that address this issue are few, because extremely 
long follow up and information on breast cancer specific mortality are required. 
Furthermore, since frozen tumor archives are unavailable from suitably large patient 
populations, gene expression technologies must be applicable to degraded RNA extracted 
from formalin fixed paraffin embedded tissues that are necessarily more than a decade 
old.  
Our group has assembled and published several technological and statistical 
approaches to address prognosis in ER+ breast cancer. We therefore sought to compare 
clinicopathological, immunohistochemical and molecular methodologies in a single 
independent test set in order to identify the best approach. Importantly, we focused on 
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fixed statistical models that were previously trained on independent data sets to avoid 
overoptimistic results. The models we report in this paper include the use of standard 
pathological factors, such as centrally-reviewed histological grade, as incorporated into 
Adjuvant! Online [8], models based on immunohistochemistry (IHC) for biomarkers of 
intrinsic subtypes [6], and a gene expression assay using fifty genes (PAM50). The latter 
represents a reduced gene set, amenable to assay by techniques such as quantitative real 
time reverse transcriptase PCR (qRT-PCR), that accurately identifies the major intrinsic 
biological subtypes of breast cancer and generates risk of relapse scores [9]. The 
investigation utilized a large independent cohort of formalin fixed, paraffin-embedded 
pathology specimens from patients with ER+ breast cancer, all M0 but otherwise 
representing a spectrum of T and N stages including a large fraction of node positive 
patients. All patients received adequate local treatment, five years of tamoxifen therapy 
but no adjuvant chemotherapy, and were followed for relapse free (RFS) and disease 
specific survival (DSS) for over a decade. 
METHODS 
Patient and sample characteristics: The study cohort was accrued from female 
patients with invasive breast cancer, diagnosed in British Columbia between 1986 and 
1992. Cancer tissue from these patients had been frozen and shipped to Vancouver 
Hospital for central ER and progesterone receptor (PR) testing by dextran-coated 
charcoal ligand binding assay. The PAM50 assay was conducted on the portion of this 
tissue that was formalin-fixed and paraffin-embedded for histologic correlation. 
Characteristics of this cohort have been previously described [6], and the same source 
blocks were used to assemble tissue microarrays for previously published studies on ER 
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[10], HER2 [11], PR [12], Ki67, cytokeratin 5/6 and epidermal growth factor receptor [6, 
13]. Quantitative ER was determined using the Ariol automated digital imaging system 
[14], and the same method was applied for PR. For this study, we selected samples from 
patients with ER+ tumors by immunohistochemistry (IHC) who had received tamoxifen 
as their only adjuvant systemic therapy. Provincial guidelines from that time period 
recommended tamoxifen for women >50 years of age, whose ER status was positive or 
unknown, and who were either node positive or had lymphovascular invasion. Cohort 
identification and sample selection for this study are summarized as per REMARK 
criteria [15] in Table 1.  
RNA preparation: H&E sections from each block were reviewed by a pathologist 
(TON). Areas containing representative invasive breast carcinoma were selected and 
circled on the source block. RNA was recovered using the High Pure RNA Paraffin Kit 
including an on-column DNase I treatment to remove any residual DNA (Roche Applied 
Science, Indianapolis IN). RNA yields were assessed using an ND-1000 
Spectrophotometer (NanoDrop Technologies, Rockland DE), and samples used for 
analysis where the concentration of total RNA exceeded 25 ng/uL and yield exceed 1.2 
ug. 
qRT-PCR: cDNA synthesis was completed using a mixture of random hexamers 
and gene-specific primers, and qPCR was performed with the Roche LightCycler 480 
instrument as previously described [9]. Each 384-well plate contained samples and a 
calibrator in triplicate with 2.5 ng cDNA and 10 ng cDNA, respectively per reaction. A 
tumor sample was considered of insufficient quality if any of the reference controls 
(ACTB, PSMC4, RPLP0, MRPL19, or SF3A1) failed. Since the expression of one of the 
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50 discriminator genes may not be detected by PCR due to a technical failure or due to 
the biology of the sample (i.e. that gene is not expressed by the tumor at a measureable 
level) we developed validation rules to distinguish between these possibilities. A 
technical failure occurred if 1) the calibrator failed in all replicates, 2) the calibrator Cps 
were out of range for that gene, or 3) all calibrators had secondary melting peaks greater 
than three-quarter the height of the specific melting peak. If the negative and calibrators 
passed, then a gene could be assigned a low copy value. The low copy was a Cp=40 for 
that gene. This value was assigned if either 1) all 3 sample replicates had Cp=0, or 2) all 
sample replicates had a Cp>35 with non-specific melting peaks, or 3) there was PCR 
amplification with a Cp>38. If both low copy and a measurable copy number value were 
assigned for sample replicates, then the measurable copy value was used.  
Subtype assignment by the 50 gene classifier: Gene expression microarrays have 
been extensively used to characterize gene expression variation in breast cancer. The 
predominant variation has been characterized as 5 “intrinsic” subtypes of breast cancer 
that have been repeatedly observed [23].  A 50 gene qRT-PCR assay has been 
constructed to provide stable and highly repeatable subtype classification in relevant 
tissue specimens (FFPE and frozen). A complete description of the development and 
initial evaluation of this assay was described in Parker et al.[9]. 
Development of the classifier began with a set of over 200 samples with 20k 
expression measurements by microarray and 160 genes measured by qRT-PCR. The 
microarray data allowed identification of gold standard specimens representing each of 
the five primary breast cancer subtypes. The set of 160 qRT-PCR genes was then 
optimized to identify a reduced subset of genes from which accurate subtype 
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classification could still be performed. A set of 50 genes was finalized using cross-
validation. The 50 genes, corresponding centroids, and other parameters of the nearest 
centroid breast cancer intrinsic subtype classifier are available in Parker et al. [9]. 
The qRT-PCR assay consists of these 50 genes and an additional 5 housekeeper 
genes used for sample normalization. Analysis by qRT-PCR is performed by first 
normalizing the raw Ct values to gene specific technical controls followed by 
normalization to the sample controls (housekeepers) [6]. The distance to each centroid is 
calculated using Spearman's rank correlation. The centroid associated with the largest 
positive correlation value is assigned as the subtype of the sample. This protocol 
produces reproducible subtype correlations and subtype assignment independently for 
each sample. 
Risk models of the 50 gene based subtype: Subtype classification of a breast 
tumor may provide insight into the prognosis and illuminate potential treatment 
strategies. However, variation exists within each subtype, and this variation carries useful 
prognostic information. Thus the prognostic value of the gene expression information is 
not limited to the final subtype assignment.  
Development of the ROR risk of relapse models consisted of assignment of the 
five subtype correlations to each sample as described above. This was performed using 
set of node negative patients with no adjuvant systemic therapy. The four tumor subtype 
(normal-like excluded) correlations were related to relapse free survival as additive terms 
in a Cox model. Ridge regression was performed in the context of cross-validation to 
optimize the weights for each term. This model of the four tumor subtype correlations 
(equation 1) provides the subtype based risk of relapse (ROR-S):  
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(equation 1) ROR-S = 0.05*Basal + 0.12*Her2 -0.34*LumA + 0.23*LumB  
Tumor size was found to be an independent prognostic factor and was included in the 
model as an additive term. Tumor size was limited to binary information ( <=2cm vs 
>2cm) as this was the data available in the training set. The weights were re-learned using 
the same process to produce a combined model of tumor size and subtype. This model 
was previously termed ROR-C [9] and is given in equation 2. The current manuscript has 
renamed this metric from ROR-C to ROR-T to distinguish this combined model from 
other combined models that are evaluated. 
 (equation 2) ROR-T = ROR-C = 0.05*Basal + 0.11*Her2 -0.23*LumA + 
0.09*LumB + 0.17*T 
Additional models were explored using the same process as was used to develop these 
models. The process of model development and the training data for these novel models 
is identical to that described above (and more completely in [9]) for ROR-S and ROR-T. 
The motivation behind these models was to incorporate proliferation information as an 
independent factor with respect to subtype. The 50 gene set contains many genes that are 
known markers of proliferation. A set of 11 proliferation genes was highly correlated (r > 
0.8) in qRT-PCR and microarray training sets (Table 2). These 11 genes were 
summarized by averaging the normalized expression estimates in each sample.  This 
proliferation signature index was modeled as an additional term to the four subtypes to 
produce ROR-P (equation 3), and in addition to the model of four subtypes and tumor 
size to produce ROR-PT (equation 4). 
(equation 3) ROR-P = -0.001*Basal + 0.7*Her2 -0.95*LumA + 0.49*LumB + 
0.34*Prolif 
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(equation 4) ROR-PT = -0.001*Basal + 0.73*Her2 -0.9*LumA + 0.05*LumB + 
0.13*T + 0.33*Prolif 
Thresholds for all four models were identified in the training set using the same process. 
The distribution of risk scores from each model was stratified by the subtype assignment. 
The low risk threshold for each model was assigned as the minimum of all Luminal B 
scores, and the high risk threshold was the maximum of all Luminal A scores. 
Luminal gene signature: Evaluation of the information content of ER protein and 
ESR1 gene expression are compared to a summarized luminal gene expression signature.  
This gene expression signature was constructed in a similar fashion to the proliferation 
signature. Specifically, a set of 8 genes was highly correlated (r > 0.8) in qRT-PCR and 
microarray training sets (Table 3) and clearly distinguished luminal tumors. These 8 
genes were summarized by averaging the normalized expression estimates in each 
sample.   
Risk models based on standard clinical data and immunohistochemically-
determined intrinsic subtype: The accuracy of risk classification is an important measure 
for comparing the various models. Other variables such as standard clinical risk factors 
and immunohistochemistry (IHC) based subtype may also be compared in this context if 
appropriate models are available. Pathological grade and IHC based subtype assignments 
are correlated with the 50 gene based subtype assignments, and independent of 
pathological stage with respect to prognostic information [9,7]. Formal models of these 
variables are needed to evaluate which of these three biologic measures best compliments 
pathologic stage to produce the most accurate classification. 
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The online decision making tool Adjuvant! Online (www.adjuvantonline.com) 
was used to generate breast cancer specific survival (BCSS) estimates for each patient in 
this cohort [27]. The clinical and pathologic factors used to generate the risk estimates 
were age, tumor size, tumor grade, ER status, number of positive lymph nodes, and 
lymphovascular invasion. 
A model of immunohistochemical subtype and tumor size (IHC-T) was 
constructed following the same process outlined for development of the ROR scores. 
Specifically, the two categorical variables were treated as additive terms in the Cox 
models, fit with Ridge regression, and optimized with cross-validation. Cross-validation 
was performed by randomly selecting 2/3 of the samples for training with the remaining 
1/3 used for validation. The process was repeated 100 times to evaluate model 
performance. IHC subtype definitions for Luminal A and B follow the protocol described 
in Cheang et al. [13], and incorporate the information from ER, PR, HER2 and Ki67 
immunohistochemistry: Luminal A = (ER or PR) positive and HER2 negative and Ki67 
<= 13%; Luminal B = (ER or PR) positive and (HER2 positive or Ki67 > 13%); HER2 = 
ER negative and PR negative and HER2 positive; basal = ER negative and PR negative 
and HER2 negative and (ck5/6 or EGFR) positive. 
The data set used for training these models has been previously described[6] and 
was derived concurrently with the test set data on the same tissue microarray series 
(making the technical aspects of immunohistochemistry performance and scoring 
identical between training and test set). This training cohort consists of 1545 node 
negative samples from patients who received no adjuvant systemic therapy. Tumor size, 
IHC subtype, pathological grade, and lymphovascular invasion were significant 
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predictors (p < 0.05) of relapse free survival in standard Cox multivariable analysis. 
Grade-T and IHC-T models were evaluated during cross-validation. As with the ROR 
models, relapse free survival, where any relapse was considered an event, was used for 
training. Accuracy estimates from cross-validation are illustrated in Figure 1. The final 
risk scores assigned to each possible level of a sample are provided in Table 4. These 
values were assigned to the estrogen receptor positive, tamoxifen-treated series samples 
(described in the main paper) as appropriate for the comparative evaluations presented. 
Relation of clinicopathological factors, intrinsic subtypes and risk of relapse 
(ROR) scores to clinical outcome: Statistical analyses were conducted using SPSS v16.0 
and R v2.8.0. Univariable analyses of tumor subtype against breast cancer relapse-free 
survival (RFS) and disease-specific survival (DSS) were performed by Kaplan-Meier 
analysis with log rank test. Multivariable analyses were performed against the standard 
clinical parameters of tumor size, nodal status, histological grade, patient age and HER2 
status. HER2 scores were centrally-determined based on assay of adjacent cores from the 
same source blocks, assembled into tissue microarrays and subjected to IHC and 
fluorescent in situ hybridization (FISH) analysis using clinical equivalent protocols [11]. 
Cox regression models [16] were built to estimate the adjusted hazard ratios of the qRT-
PCR-assigned breast cancer subtypes, as well as ROR scores categorized by published 
cut-points and as a continuous variable. IHC based subtypes were assigned as previously 
defined [6]. The online decision making tool Adjuvant! Online 
(www.adjuvantonline.com), previously validated on the British Columbia population 
cohort [8], was used to generate breast cancer relapse-free and disease-specific survival 
estimates for each patient in this cohort. Only cases with information for all the 
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covariates were included in the analyses. Smoothed plots of weighted Schoenfeld 
residuals were used to assess proportional hazard assumptions [17] and time 
stratifications were employed where hazards were not proportional over the entire follow 
up period.  
The C-index [18] is defined as the probability that risk assignments to members of 
a random pair are accurately ranked according to their prognosis. The number of 
concordant pairs (order of failure and risk assignment agree), discordant pairs (order of 
failure and risk assignment disagree), and uninformative pairs are tabulated to calculate 
the measure. C-index values of 0.5 indicate random prediction and higher values indicate 
increasing prediction accuracy. Variability in the C-index for each predictor and p-values 
from comparisons were estimated from 1000 bootstrap samples of the risk assignments. 
Calculation was performed using the rcorr.cens function implemented in the Hmisc [19] 
library for R statistical software version 2.8.1 (http://www.R-project.org). 
INTRINSIC SUBTYPING OF ER POSITIVE, TAMOXIFEN-TREATED BREAST 
CANCER USING THE PAM50 ASSAY 
RNA was extracted from pathologist-guided tissue cores from 991 formalin-fixed, 
paraffin-embedded breast cancer specimens. 811 samples yielded sufficient RNA for 
analysis (at least 1.2 ug total RNA at a concentration = 25 ng/uL). Template was 
technically sufficient in 786 cases, based on all internal housekeeper gene controls being 
expressed in the sample above background. Clinical characteristics for the patients 
included in the PAM50 analysis are presented in Table 5 (Tables 6 and 7 provide details 
stratified by node status). Based on the nearest PAM50 centroid algorithm, intrinsic 
breast cancer subtypes were assigned using gene expression as follows: 372 samples 
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(47.3%) were Luminal A, 329 (41.9%) Luminal B, 64 (8.1%) HER2-enriched, 5 (0.6%) 
Basal-like, and 16 (2.0%) Normal-like. Thus, while all cases in this study were positive 
for ER by centrally-assessed IHC analysis on a tissue microarray (10), and 98.8% were 
also positive by dextran-charcoal coated biochemical assay (Table 5), the gene expression 
panel nevertheless assigned 9% of cases into non-luminal subtypes, mostly HER2-
enriched. This phenomenon has been previously observed when interrogating published 
datasets for expression of the PAM50 genes [9]. For the sixteen cases assigned as 
Normal-like, histology was reviewed from adjacent tissue cores, and in 14 of 16 cases 
invasive cancer cells were absent or rare. Normal-like cases were therefore excluded 
from outcome analyses, as a breast cancer subtype could not be confidently assigned due 
to insufficient tumor content. 
The intrinsic biological subtypes were strongly prognostic by Kaplan-Meier 
analysis (Figures 2A and 2B). In the British Columbia population at the time these 
samples were originally acquired, many patients with a clinically low-risk profile 
received no adjuvant systemic therapy [8]. In contrast, those receiving adjuvant 
tamoxifen (the subjects of this study) had tumors that were mostly node positive, high 
grade and/or exhibited lymphovascular invasion, and therefore constitute a higher risk 
group with overall 10 year RFS of 62% and DSS of 72%. Those assigned by the PAM50 
assay to Luminal A status had a significantly better outcome (10 year relapse free 
survival 74%, diseasespecific survival = 83%) than Luminal B, HER2-enriched or basal 
like tumors (Figure 2A for RFS and Figure 2B for DSS). The ROR risk-of-relapse 
algorithms [9] were originally trained on microarray data from node negative patients 
who received no adjuvant systemic therapy, and have not previously been applied to a 
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population homogeneously-treated with adjuvant tamoxifen, nor to a series containing 
large numbers of node positive cases, nor to the endpoint of disease specific survival. In 
this data set ROR-S (a model based solely on gene expression) nevertheless showed 
performance consistent with our previous report (Figures 2C and 2D).  
Multivariable Cox models were constructed to test the independent value of 
PAM50 subtyping against standard clinical and pathological factors including age, 
histological grade, lymphovascular invasion, HER2 expression, nodal status, and tumor 
size. To meet proportional hazard assumptions, multivariable models were assessed with 
the time axis split at 5 years [20], as HER2-enriched and basal-like tumors (Figure 2A 
and 2B) and ROR-S high category tumors (Figure 2C and 2D) had a much higher event 
rate inthe first five years than subsequently. The intrinsic biological subtype and ROR-S 
remained significant in the multivariable models for DSS (Table 8) and RFS (Table 9), 
particularly in the first five years, as did pathological staging variables (tumor size and 
node status). However histological grade, lymphovascular invasion and clinical HER2 
status, significant in univariable analysis in this cohort, no longer contributed significant 
independent prognostic information when the multivariable analysis included the PAM50 
assignments.  
COMPARISONS BETWEEN GENE EXPRESSION AND CLINICAL ASSAYS FOR 
HORMONE RECEPTORS AND PROLIFERATION 
In a case that is ER positive by immunohistochemistry, additional information 
about hormone receptor expression can be obtained in several ways, including dextran 
coated charcoal ligand binding assay, quantitative immunohistochemistry for ER, or 
equivalent measures of progesterone receptor (PR). Most published assays for breast 
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cancer prognosis in ER+ disease include tumor growth rate as one of the parameters in 
the statistical model, and this dataset was previously assessed in detail for 
immunohistochemical Ki67 index [6]. The PAM50 qRT-PCR data allows detailed 
quantitative assessment of the functionality of the estrogen response pathway (8 gene 
luminal signature) as well as a proliferation signature based on the mean expression of 
eleven genes linked to cell cycle progression (trained on published data, as per 
Supplementary Methods). The availability of all these measurements [10] provides an 
opportunity to determine which approach most accurately captures the prognostic effect. 
of estrogen pathway biomarkers and tumor growth rate in a direct comparison (Figure 3). 
Given a randomly selected pair of subjects, the concordance index (C-index) is the 
probability that the patient assigned the more extreme risk score actually has a worse 
prognosis. A value of 0.5 indicates discrimination that is no better than chance prediction, 
and a value of 1 indicates perfect discrimination of samples. Using the C-index to 
compare prognostic capacity in this uniformly tamoxifen-treated cohort, the combination 
of luminal genes measured by the PAM50 yields more prognostic information than other 
methods of hormone receptor analysis, but the differences are not significant. Although 
Ki67 index by immunohistochemistry appears to outperform quantitative ER, the 
proliferation signature provides the most robust approach for the prediction of both RFS 
and DSS (Figure 3, Table 10). Multivariable analysis indicated that the Ki67 
immunohistochemical assay did not contribute significant independent information to 
prognostic models for either node negative or node positive breast cancer patients, when 
information on the proliferation signature is included (Table 11). 
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COMPARISON OF FIXED MODELS OF PROGNOSIS IN NODE NEGATIVE 
BREAST CANCER 
For formal model comparisons, data was generated on four fixed approaches, 
without any element of training within the test set: a) clinical model based on Adjuvant! 
Online, b) IHC-based (incorporating data on Ki67 and HER2), c) the ROR-S approach 
based on PAM50 gene expression alone, and d) the proliferation signature alone and as 
incorporated into the ROR-P risk model using a beta coefficient weighting for 
proliferation (described in Supplementary Methods). Adjuvant! Online incorporates full 
tumor size staging information; to account for the influence of tumor size the biomarker 
models were also weighted by a beta coefficient (T) that incorporated the prognostic 
information associated with T1 status versus higher T stage (the level of detail available 
in the independent training sets). This approach created IHC-T, ROR-T and ROR-PT 
models. In addition, the strong independent influence of N stage was accounted for by 
conducting the analysis separately in the N0 and N+ populations.  
C-index assessments showed superiority of the biomarker models over the purely 
clinical Adjuvant! Online model in the node negative population, with the ROR-PT 
approach providing the most prognostic information (Figure 4A). In multivariable 
analysis, the addition of ROR-P to a model of ROR-S results in a significant increase in 
explained prognostic variation (RFS p=0.0032; DFS p=0.0015); ROR-PT is also 
significant after conditioning on ROR-S (RFS p= 0.0023; DFS p=0.0015) but not ROR-P 
(RFS p=0.12; DFS p=0.13). A continuous score based on the ROR-PT was generated to 
translate the data into an individual RFS and DSS risk assessment tool (Figure 4B). 
Kaplan Meier analysis illustrates the ability of the ROR-PT model to identify patients 
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who have an extremely high chance (>95%) of remaining disease free (Figure 4C) and 
alive beyond 10 years (Figure 4D). In contrast, our previously published IHC model (6), 
could not identify a group with sufficiently favorable outcomes that five years of 
tamoxifen might be considered adequate treatment (i.e. <90% 10 yr RFS; Figures 4E and 
4F).  
COMPARISON OF FIXED MODELS OF PROGNOSIS IN NODE POSITIVE 
BREAST CANCER 
For node positive disease, C index analysis (Figure 5A) supports the conclusion 
that the ROR-T score produces the best prognostic model; in contrast to N0 disease, the 
proliferation signature added relatively little information and proliferation weighting 
(ROR-PT) did not yield a superior model. Adjuvant Online! performed almost as well, 
but had the advantage of incorporating the actual number of involved lymph nodes. This 
information was not available in the independent training sets used to build the ROR 
models, and so could not be used in the current analysis (which can however serve to 
train future models incorporating number of involved lymph nodes). The continuous 
score model for node positive disease (Figure 5B) produces a very broad range of 
prognosis, similar to N0 disease, although few patients have a prognosis in the range 
where tamoxifen monotherapy for five years would be considered sufficient treatment. 
While there were large and highly significant differences in survival in ROR-defined risk 
groups, Kaplan Meier analysis (Figures 5C-5D) illustrates that even patients in the lowest 
risk ROR group are still subject to relapses and late deaths from breast cancer, 
particularly after the fifth year of follow up. The immunohistochemistry-based risk model 
incorporating Ki67 and HER2 also produces a statistically significant prognostic impact 
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for RFS (Figure 5E) and DSS (Figure 5F), although these differences are narrower than 
those achieved by the gene expression-based model. 
 
DISCUSSION  
Previous studies have established that intrinsic biological signatures are present and have 
prognostic significance in breast cancer cohorts from multiple different institutions, 
profiled with several gene expression microarray platforms [21-24]. In order to identify 
these subtypes on standard formalin-fixed, paraffin-embedded pathology specimens, we 
developed a qRT-PCR test based on a panel of 50 genes [9]. The analysis reported here 
applied this test to a series of paraffin blocks with > 15 years detailed followup.  
Whereas previously assessed cohorts consisted mainly of low risk women 
receiving no adjuvant systemic therapy, or were heterogeneously-treated, the cases in the 
current study are all women with estrogen receptor positive breast cancer who received 
endocrine therapy as their sole adjuvant treatment, a group of particular clinical 
importance and contemporary relevance. In this analysis we sought to compare different 
technologies for predicting long term outcomes for such patients. In this study cohort, 
patients were diagnosed with node positive or higher risk N0 disease. Only 8% of the N0 
population had grade 1 disease and 55% exhibited lymphovascular invasion (Table 6). 
Under the current standard of care in most countries the majority of these patients would 
now be treated with adjuvant chemotherapy [25] and extended endocrine therapy. Using 
a series of fixed models trained in independent data sets, we compared a standard 
approach using clinico-pathological information (Adjuvant! Online), to our published 
Luminal B discriminator based on Ki67 and HER2 immunohistochemistry additionally 
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weighted for T stage (IHC-T), and to PAM50 gene expression based ROR models 
weighted for T stage (ROR-T and ROR-PT). In node-negative patients, the ROR-PT 
approach was the most accurate and was able to identify patients in whom 5 years of 
tamoxifen may be adequate treatment based on the very low late relapse rate in the 5 to 
10 year window (Figure 4C). In node positive disease, the PAM50 approach represents 
an advance in prognostication, but late relapses and deaths were seen even in the lowest 
risk group identified using the best ROR model. Unlike in N0 disease, proliferation 
signature weighting did not improve the C index in node positive disease.  
On this cohort, detailed centrally-determined immunohistochemical analyses have 
previously been performed and published [6, 10-13, 26]. C-index, Kaplan-Meier and Cox 
model analyses show that immunohistochemical approaches do work and provide 
significant prognostic information. However, the PAM50-based models are superior in 
terms of adding significant additional information and in their capacity to identify a 
particularly low-risk group of women.  
We view these PAM50 models, derived from archival formalin fixed RNA, as a 
potential replacement for grade, hormone receptor, Ki67 and HER2 based prognostic 
models, but not as a replacement for pathological stage (as tumor size and nodal status 
remain independent predictors in multivariable models that include PAM50 based 
prognostic information). One weakness of our approach is that our current accounting for 
pathological stage is over-simplified due to the limited stage distributions and clinical 
information in our training sets. We analyzed the data as either node negative or node 
positive, and accounted for T stage by categorizing the samples as either T1 or greater. A 
future aim is to integrate the PAM50 data into the Adjuvant! Online approach (27) to 
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more completely account for the prognostic influence of pathological stage. To achieve 
this we would need to construct a training set that adequately includes all the 5 categories 
of T size and four categories of N stage used in Adjuvant! Online, in order to gauge the 
prognostic weight of these pathological stage categories in the setting of PAM50 
information. Additionally, incorporation of all immunohistochemical data as continuous 
variables in a combined model may improve its prognostic value. The current series 
contains sufficiently detailed clinical and immunohistochemical information to contribute 
to such detailed comparisons, as a training set requiring further validation.  
An additional caveat to our study is that the population was strongly biased 
towards higher risk breast cancers and so likely underestimates of the number of patients 
in the broader, node negative population for whom adjuvant tamoxifen would represent 
adequate treatment. The current generation of adjuvant aromatase inhibitor trials would 
be an appropriate setting to address the value of our approach further. We accept the 
possibility that a better model using Ki67 at a different cut point could be developed. 
However since we were focused on comparing fixed models, we used our published 
approach. Further work on the Ki67 model and cut point optimization will require 
independent data sets.  
In comparison with other signatures such as the recurrence score and genomic 
grade index [1, 28, 29], the PAM50 has the potential advantage of discriminating high 
risk patients into Luminal B, HER2-Enriched and Basal-like subtypes, who are likely to 
respond differently to the main systemic therapy options (endocrine, anti-HER2, and 
anthracycline vs. non-anthracycline vs. taxane chemotherapy regimens). The assay 
requires neither frozen tissue (30) nor manual microdissection of cut sections(1), and can 
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be readily applied to standard paraffin blocks including archival tissues from clinical 
trials. Currently available assays such as Mammaprint (31) and OncotypeDX (32) were 
optimized to recognize particularly low risk patients from among a node negative early 
stage population who did not receive chemotherapy. Because intrinsic subtyping is 
designed to identify discriminative biological features of breast cancer, rather than being 
derived around clinical outcome in a specific population, this approach is particularly 
likely to extrapolate well onto other patient cohorts [33]. The current study demonstrates 
the ability of PAM50 to recognize a very low risk prognostic group among women 
receiving tamoxifen and no chemotherapy, similar to the Oncotype Dx assay [34, 35]. A 
direct comparison of different expression profile approaches may become possible in the 
future through a reanalysis of cohorts with the PAM50 that have already been analyzed 
by OncotypeDX, since both assays can be applied to the same source material. Our 
inability to identify a group of patients with node positive disease in whom five years of 
tamoxifen is adequate is reminiscent of the recent findings from the Southwest Oncology 
Group, who also found that a molecular signature for good outcome in N0 disease failed 
in node positive disease in this regard [35]. It would be relevant to study a series of 
patients treated with extended adjuvant aromatase inhibitor therapy, who will have even 
lower residual risk, as some of the patients in the low risk N+ group may simply require 
longer treatment with modern endocrine therapy rather than chemotherapy.  
The development of new approaches for defining prognosis in N+ disease is also 
warranted. We have already established the preoperative endocrine prognostic index 
(PEPI), which demonstrated that the “on endocrine treatment” Ki67 value is more 
effective than baseline Ki67 for the identification of patients with clinical stage 2 and 3 
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disease who have excellent long term outcomes after neoadjuvant endocrine therapy [36]. 
A comparison between Ki67 and the PAM50 based proliferation signature in the 
neoadjuvant endocrine therapy setting is therefore one logical next step.  
The applicability of this test to formalin-fixed paraffin-embedded tissues will 
make possible its use on large clinical trial archives that address this issue [37]. The 
results of our study highlight the feasibility of measuring multi-gene expression panels on 
such series as a means for demonstrating clinical utility, using a method readily 
applicable to prospective clinical samples that provides more prognostic information than 
clinical or standard immunohistochemical approaches.  
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TABLES 
 
Table 1. Cohort identification and sample selection. 
 
 
Table 2.  Genes used in the proliferation index. 
Genes in proliferation index 
GeneName UniGene EntrezGene 
BIRC5 Hs.514527 332 
CCNB1 Hs.23960 891 
CDC20 Hs.524947 991 
NUF2 Hs.651950 83540 
CEP55 Hs.14559 55165 
NDC80 Hs.414407 10403 
MKI67 Hs.80976 4288 
PTTG1 Hs.350966 9232 
RRM2 Hs.226390 6241 
TYMS Hs.592338 7298 
UBE2C Hs.93002 11065 
  
Table 3. Genes used in the luminal signature. 
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Selection criteria Sample Size 
British Columbia breast cancer cases submitted for central ER testing (1986-1992).  Cases with complete 
outcome and FFPE block containing histologically representative invasive breast cancer. 4046 
Cases receiving Tamoxifen as sole adjuvant systemic therapy 1305 
IHC ER positive on tissue microarray 1075 
Samples sent for qRT-PCR 991 
RNA extraction with 1.2 ug total RNA yield at a concentration of at least 25 ng/uL 811 
Samples with PAM50 assignments 786 
Luminal A/B, HER2-enriched or Basal-like (Normal-like breast cancer – excluded from analyses) 770 (16) 
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Table 4. Model weights for the IHC-T model. 
 
IHC-T 
IHC subtype Tumor size Risk Score 
Luminal A <= 2cm 0 
Luminal A > 2cm 0.23 
Luminal B <= 2cm 0.4 
Luminal B > 2cm 0.64 
Her2 <= 2cm 0.44 
Her2 > 2cm 0.67 
Basal <= 2cm 0.15 
Basal > 2cm 0.38 
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Table 5. Clinical characteristics of the whole cohort. 
 
  
Clinical parameter Total PAM50 subtype (all n=786) 
Luminal A Luminal B Her2 Basal Normal 
Sample Size N 786 372 329 64 5 16 
follow-up times in 
recurrence-free 
patients (yr) 
median 
(min. – max.) 
9.7 
(0.12-18) 
12  
(0.25-18) 
7.6  
(0.12-18) 
7.3 
(0.47-18) 
2.3  
(0.6-4.1) 
13  
(3.2-18) 
followup-times in 
disease specific 
surviving patients (yr) 
median 
(min. – max.) 
12 
(0.55-18) 
13  
(0.57-18) 
10  
(0.64-18) 
8.8 
(0.55-18) 
5  
(1.6-16) 
14  
(3.2-18) 
age (yr) median 67 67 68 66.5 65 68.5 
pre-menopausal yes 20 10 7 2 1 0 
no 752 358 314 62 4 14 
unknown / 
pregnant 
14 4 8 0 0 2 
surgery Complete 
mastectomy 
mastectomy 
468 210 203 39 5 11 
partial 
mastectomy 
306 159 119 23 0 5 
other 12 3 7 2 0 0 
axillary node 
dissection 
yes 745 349 313 62 5 16 
no 41 23 16 2 0 0 
radiation therapy yes 419 207 164 40 1 7 
no 367 165 165 24 4 9 
tumour size (cm) median 2.1 2.0 2.5 2.5 3.5 2.3 
T stage (clinical) T0 / IS 1 0 0 0 0 1 
T1 331 180 118 27 3 3 
T2 380 165 179 28 2 6 
T3 18 9 5 3 0 1 
T4 34 10 17 3 0 4 
TX 22 8 10 3 0 1 
# positive nodes 0 222 95 97 19 1 10 
1-3 360 182 148 26 1 3 
4-9 125 55 53 12 2 3 
10+ 26 10 14 2 0 0 
unknown 53 30 17 5 1 0 
grade grade 1: well 
differentiated 
34 25 5 1 1 2 
grade 2: 
moderately 
differentiated 
338 186 129 14 0 9 
grade 3: poorly 
differentiated 
370 135 179 48 3 5 
unknown 44 26 16 1 1 0 
histologic subtype ductal NOS 708 329 302 60 4 13 
lobular 61 32 21 4 1 3 
mucinous 7 4 3 0 0 0 
tubular 7 6 1 0 0 0 
medullary 2 1 1 0 0 0 
apocrine 1 0 1 0 0 0 
lymphovascular 
invasion 
yes 485 210 220 44 2 9 
no 262 139 94 19 3 7 
unknown 39 23 15 1 0 0 
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Table 6. Clinical characteristics of the node negative (N0) cohort. 

 
  
Clinical parameter Total 
PAM50 subtype (N0: n=222) 
Luminal 
A 
Luminal 
B Her2 Basal Normal 
Sample Size N 222 95 97 19 1 10 
age (in years) median 66 66 68 64 44 71 
pre-menopausal 
yes 6 1 3 1 1 0 
no 211 94 90 18 0 9 
unknown / pregnant 5 0 4 0 0 1 
surgery 
complete 
mastectomy 115 43 55 10 1 6 
partial mastectomy 107 52 42 9 0 4 
other 0 0 0 0 0 0 
axillary node dissection yes 222 95 97 19 1 10 
no 0 0 0 0 0 0 
radiation therapy yes 112 54 44 10 1 3 
no 110 41 53 9 0 7 
tumour size (cm) median 2.0 1.9 2.1 2.5 9.9 2.3 
T stage (clinical) 
T0 / IS 1 0 0 0 0 1 
T1 99 52 39 5 0 3 
T2 105 39 51 11 1 3 
T3 2 1 0 1 0 0 
T4 9 2 3 1 0 3 
TX 6 1 4 1 0 0 
# positive nodes 
0 222 95 97 19 1 10 
1-3 0 0 0 0 0 0 
4-9 0 0 0 0 0 0 
10+ 0 0 0 0 0 0 
unknown 0 0 0 0 0 0 
grade 
grade 1: well 
differentiated 18 13 2 0 1 2 
grade 2: moderately 
differentiated 100 50 40 4 0 6 
grade 3: poorly 
differentiated 97 29 51 15 0 2 
unknown 7 3 4 0 0 0 
histologic subtype 
ductal NOS 189 77 86 18 0 8 
lobular 25 11 10 1 1 2 
mucinous 2 2 0 0 0 0 
tubular 5 5 0 0 0 0 
medullary 1 0 1 0 0 0 
apocrine 0 0 0 0 0 0 
lymphovascular invasion 
yes 118 42 59 12 0 5 
no 97 48 36 7 1 5 
unknown 7 5 2 0 0 0 
clinical estrogen receptor status 
(DCC) 
missing 3 2 1 0 0 0 
negative (0-9 fmol/mg) 2 2 0 0 0 0 
positive (>10 fmol/mg) 217 91 96 19 1 10 
median (fmol/mg) 261.0 279.0 324.5 178.5 32.0 53.0 
immunohistochemical HER2 with 
FISH correction on 2+ cases 
negative 200 91  87  11  1  10 
positive 18 1  9  8  0  0  
unknown 4 3  1  0  0  0 
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Table 7. Clinical characteristics of the node positive cohort. 
 
 
 
  
Clinical parameter Total 
PAM50 subtype (N+: n=511) 
Luminal 
A 
Luminal 
B Her2 Basal Normal 
Sample Size N 511 247 215 40 3 6 
age (in years) median 67 67 68 67 65 63.5 
pre-menopausal 
yes 13 9 3 1 0 0 
no 490 234 209 39 3 5 
Unknown/ pregnant 8 4 3 0 0 1 
surgery 
Complete 
mastectomy 336 158 144 26 3 5 
partial mastectomy 171 87 69 14 0 1 
other 4 2 2 0 0 0 
axillary node dissection yes 510 247 214 40 3 6 
no 1 0 1 0 0 0 
radiation therapy yes 283 140 111 28 0 4 
no 228 107 104 12 3 2 
tumour size (cm) median 2.4 2.0 2.5 2.5 3.5 2.3 
T stage (clinical) 
T0 / IS 0 0 0 0 0 0 
T1 206 112 73 19 2 0 
T2 262 118 123 17 1 3 
T3 13 6 5 1 0 1 
T4 17 5 10 1 0 1 
TX 13 6 4 2 0 1 
N stage (pathological) 
N0 0 0 0 0 0 0 
N1 496 242 208 37 3 6 
N2 14 5 6 3 0 0 
N3 1 0 1 0 0 0 
NX 0 0 0 0 0 0 
# positive nodes 
0 0 0 0 0 0 0 
1-3 360 182 148 26 1 3 
4-9 125 55 53 12 2 3 
10+ 26 10 14 2 0 0 
unknown 0 0 0 0 0 0 
grade 
grade 1: well 
differentiated 12 9 2 1 0 0 
grade 2: moderately 
differentiated 216 123 81 9 0 3 
grade 3: poorly 
differentiated 251 95 122 29 2 3 
unknown 32 20 10 1 1 0 
histologic subtype 
ductal NOS 473 227 201 37 3 5 
lobular 33 18 11 3 0 1 
mucinous 3 1 2 0 0 0 
tubular 1 1 0 0 0 0 
medullary 0 0 0 0 0 0 
apocrine 1 0 1 0 0 0 
lymphovascular invasion 
yes 343 158 152 27 2 4 
no 139 73 51 12 1 2 
unknown 29 16 12 1 0 0 
clinical estrogen receptor status 
(DCC) 
missing 4 1 2 0 0 1 
negative (0-9 fmol/mg) 7 1 2 4 0 0 
positive (>10 fmol/mg) 500 245 211 36 3 5 
median (fmol/mg) 253.0 252.5 311.0 67.0 29.0 73.0 
immunohistochemical HER2 with 
FISH correction on 2+ cases 
negative 450  231  190  20  3  6 
positive 51  11  21  19  0  0  
unknown 10 5  4  1  0  0 
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Table 8: Cox model multivariable analysis of breast cancer disease-specific survival 
among ER positive, tamoxifen-treated women, incorporating standard clinicopathological 
factors and (A) intrinsic subtype or (B) Risk of Relapse (ROR-S), as determined by 
PAM50 qRT-PCR measurements. p-values for multilevel categorical variables are 
derived from likelihood ratio tests between models with and without each these variables. 
 
  
A. Intrinsic subtype 
Clinical endpoint  
multivariable disease-specific survival 
(0 – 5 years fol lowup)  
multivariable disease-specific survival 
(5 years to end of followup)  
hazard ratio (95% CI)  p-value  hazard ratio (95% CI)  p-value  
Age 1.02 (0.99-1.05)  0.2665 1.00 (0.98-1.02)  0.9786 
Grade (1-2 vs 3) 1.51 (0.87-2.60)  0.1405 1.05 (0.71-1.56)  0.8109 
LV 1.02 (0.58-1.81)  0.9421 1.16 (0.77-1.75)  0.4852 
HER2 (IHC)  1.50 (0.77-2.91)  0.2314 0.82 (0.40-1.69)  0.5968 
Node status (N0 as reference) 
  
< 0.0001 
  
0.0012 
1-3 2.07 (0.95-4.54)    1.54 (0.96-2.47)    
4+ 5.80 (2.64-12.71)    2.78 (1.60-4.82)    
Tumor size (T1 as reference) 
  0.049   0.0002 
T2 1.22 (0.71-2.09)    1.62 (1.08-2.42)    
T3 3.92 (1.50-10.22)    5.11 (1.78-14.62)    
T4 1.31 (0.38-4.50)    4.02 (1.85-8.74)    
Subtype (Lum A as reference) 
  
0.0018 
  
0.0381 
Luminal B  1.99 (1.09-3.64)    1.70 (1.13-2.55)    
Her2-enriched 3.65 (1.64-8.16)   1.52 (0.72-3.18)   
Basal-like  17.71 (1.71-183.33)    NA   
B. Risk of relapse (ROR-S) 
Clinical endpoint  
multivariable disease-specific survival 
(0 – 5 years fol lowup)  
multivariable disease-specific survival 
(5 years to end of followup)  
hazard ratio (95% CI)  p-value  hazard ratio (95% CI)  p-value  
Age 1.02 (0.99-1.05)  0.2676 1.00 (0.98-1.02)  0.9089 
Grade (1-2 vs 3) 1.36 (0.79-2.36)  0.2674 1.01 (0.68-1.51)  0.9588 
LV 0.95 (0.54-1.66)  0.852 1.18 (0.78-1.79)  0.4299 
HER2 (IHC)  1.46 (0.77-2.77)  0.2467 0.87 (0.43-1.77)  0.6964 
Node status (N0 as reference) 
  
< 0.0001 
  
0.0014 
1-3 2.14 (1.00-4.60)    1.55 (0.97-2.48)    
4+ 6.03 (2.79-13.05)    2.78 (1.59-4.86)    
Tumor size (T1 as reference) 
  0.0647   0.0003 
T2 1.19 (0.70-2.05)    1.64 (1.10-2.45)    
T3 3.34 (1.32-8.43)    3.69 (1.30-10.46)    
T4 0.90 (0.25-3.19)    4.44 (2.01-9.78)    
ROR-S (low as reference) 
  <0.0001   0.0388 
Med 2.04 (0.89-4.66)    1.86 (1.15-3.00)    
High 6.48 (2.56-16.40)    1.57 (0.71-3.46)    

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Table 9. Cox model multivariable analysis of breast cancer relapse free survival among 
ER positive, tamoxifen-treated women, incorporating standard pathological and clinical 
factors and (A) intrinsic subtype or (B) Risk of Relapse (ROR-S), as determined by 
PAM50 qRT-PCR measurements. p-values for multilevel categorical variables are 
derived from likelihood ratio tests between models with and without each these variables.  
  
 
 
  
A. Intrinsic subtype 
Clinical endpoint  
relapse-free survival 
(0 – 5 years followup)  
relapse-free survival  
(5 years to end of followup)  
hazard ratio (95% CI)  p-value  hazard ratio (95% CI)  p-value  
Age 1.00 (0.98-1.02)  0.9813 0.99 (0.97-1.02)  0.579 
Grade (1-2 vs 3) 1.17 (0.80-1.71)  0.4112 1.10 (0.73-1.68)  0.6424 
LVI 1.01 (0.67-1.52)  0.9699 1.31 (0.84-2.06)  0.2382 
HER2 (IHC)  1.54 (0.93-2.56)  0.0941 0.32 (0.10-1.04)  0.0587 
Node status 
  
< 0.0001 
  
0.0104 
1-3 1.71 (1.03-2.83)    1.49 (0.90-2.46)    
4+ 4.12 (2.44-6.96)    2.56 (1.39-4.72)    
Tumor size 
  0.0077   < 0.0001 
T2 1.05 (0.72-1.53)    2.03 (1.30-3.15)    
T3 3.55 (1.69-7.42)    7.69 (2.32-25.56)    
T4 1.07 (0.38-3.00)    5.61 (2.44-12.89)    
Subtype 
  
0.0003 
  
0.1444 
Luminal B  1.82 (1.20-2.76)    1.52 (0.99-2.34)    
Her2-enriched 2.82 (1.55-5.13)   1.07 (0.44-2.64)   
Basal-like  9.75 (1.82-52.34)    NA   
B. Risk of Relapse (ROR-S) 
Clinical endpoint  
relapse-free survival 
(0 – 5 years followup)  
relapse-free survival 
(5 years to end of followup)  
hazard ratio (95% CI)  p-value  hazard ratio (95% CI)  p-value  
Age 1.00 (0.98-1.02)  0.8668 0.99 (0.97-1.02)  0.5048 
Grade (1-2 vs 3) 1.07 (0.73-1.57)  0.7317 1.10 (0.71-1.68)  0.672 
LVI 0.92 (0.62-1.38)  0.697 1.29 (0.82-2.04)  0.2647 
HER2 (IHC)  1.57 (0.98-2.53)  0.0607 0.32 (0.10-1.05)  0.0593 
Node status 
  
< 0.0001 
  
0.0244 
1-3 1.67 (1.02-2.73)    1.43 (0.86-2.36)    
4+ 4.32 (2.57-7.27)    2.37 (1.27-4.42)    
Tumor size 
  0.0008   < 0.0001 
T2 1.03 (0.70-1.51)    2.08 (1.33-3.24)    
T3 3.81 (1.94-7.50)    5.94 (1.78-19.84)    
T4 0.91 (0.32-2.61)    6.05 (2.61-14.02)    
ROR-S 
  <0.0001   0.2495 
Med 2.00 (1.17-3.44)    1.46 (0.90-2.38)    
High 4.54 (2.34-8.79)    1.01 (0.41-2.45)    
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Table 10 : C-index mean values and 95% confidence intervals from Figures 3, 4A and 
5A, in tabular form. Confidence intervals for the C-index estimates and p-values of 
comparisons were calculated empirically from 1000 bootstrap samples.    
 
 
 
 
 
  
RFS Change vs ER DCC Change vs Ki67 APP DSS Change vs ER DCC Change vs Ki67 (APP)
C-index (95% CI) p-value p-value C-index (95% CI) p-value p-value
ER DCC 0.54 (0.5-0.58) --- 0.938 0.561 (0.51-0.6) --- 0.761
ER APP 0.55 (0.51-0.59) 0.335 0.891 0.562 (0.52-0.6) 0.44 0.739
ESR1 qRT-PCR 0.54 (0.5-0.58) 0.54 0.946 0.542 (0.5-0.58) 0.858 0.904
PR DCC 0.565 (0.52-0.6) 0.172 0.753 0.589 (0.55-0.63) 0.16 0.427
PR APP 0.55 (0.51-0.59) 0.351 0.903 0.566 (0.52-0.61) 0.404 0.725
PGR qRT-PCR 0.581 (0.54-0.62) 0.084 0.559 0.608 (0.56-0.65) 0.068 0.194
Luminal qRT-PCR 0.577 (0.54-0.62) 0.073 0.623 0.603 (0.56-0.65) 0.058 0.222
Ki67 APP 0.585 (0.54-0.62) 0.062 --- 0.585 (0.54-0.63) 0.239 ---
MKI67 qRT-PCR 0.552 (0.51-0.59) 0.357 0.951 0.553 (0.51-0.6) 0.6 0.934
Proliferation qRT-PCR 0.617 (0.58-0.66) 0.006 0.031 0.621 (0.58-0.66) 0.035 0.025
RFS Change vs AOL Change vs IHC-T DSS Change vs AOL Change vs IHC-T
C-index (95% CI) p-value p-value C-index (95% CI) p-value p-value
Proliferation qRT-PCR 0.653 (0.58-0.72) 0.042 0.21 0.669 (0.58-0.75) 0.029 0.191
Adjuvant! 0.568 (0.49-0.65) --- 0.919 0.559 (0.46-0.65) --- 0.963
IHC-T IHC 0.615 (0.53-0.69) 0.081 --- 0.626 (0.54-0.71) 0.037 ---
ROR-S qRT-PCR 0.627 (0.55-0.71) 0.107 0.408 0.625 (0.53-0.71) 0.12 0.523
ROR-T qRT-PCR 0.65 (0.57-0.72) 0.003 0.114 0.656 (0.57-0.73) 0.004 0.127
ROR-P qRT-PCR 0.648 (0.57-0.72) 0.048 0.239 0.66 (0.57-0.75) 0.034 0.236
ROR-PT qRT-PCR 0.671 (0.59-0.74) 0.001 0.047 0.685 (0.6-0.76) 0.002 0.033
RFS Change vs AOL Change vs IHC-T DSS Change vs AOL Change vs IHC-T
C-index (95% CI) p-value p-value C-index (95% CI) p-value p-value
Proliferation qRT-PCR 0.583 (0.54-0.62) 0.868 0.601 0.6 (0.55-0.64) 0.822 0.645
Adjuvant! 0.61 (0.57-0.65) --- 0.167 0.626 (0.58-0.67) --- 0.242
IHC-T IHC 0.59 (0.54-0.63) 0.833 --- 0.611 (0.56-0.65) 0.758 ---
ROR-S qRT-PCR 0.612 (0.57-0.65) 0.504 0.145 0.645 (0.6-0.69) 0.283 0.088
ROR-T qRT-PCR 0.609 (0.56-0.65) 0.579 0.1 0.643 (0.59-0.68) 0.238 0.035
ROR-P qRT-PCR 0.593 (0.55-0.63) 0.769 0.418 0.615 (0.57-0.66) 0.663 0.418
ROR-PT qRT-PCR 0.598 (0.55-0.64) 0.719 0.305 0.622 (0.57-0.67) 0.592 0.297
Figure 2
Figure 3A
Figure 4A
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Table 11: Cox model multivariable analysis of breast cancer relapse free survival and 
disease specific survival among ER positive, tamoxifen-treated women, incorporating 
standard pathological and clinical factors in addition to proliferation measures to evaluate 
(A) node negative and (B) node positive subjects. p-values for multilevel categorical 
variables are derived from likelihood ratio tests between models with and without each 
these variables.    
 
 
 
 
 
  
A. Node Negative Subjects 
Outcome Relapse free survival Disease specific survival 
 hazard ratio (95% CI) p-value hazard ratio (95% CI) p-value 
Age 1.01 (0.97-1.05)  0.5657 1.03 (0.98-1.07)  0.24773 
Grade (1-2 vs 3) 1.22 (0.62-2.43)  0.56 0.93 (0.43-2.01)  0.85 
LVI 1.17 (0.60-2.29)  0.65 1.37 (0.64-2.94)  0.42 
HER2 (IHC)  0.30 (0.07-1.27)  0.10 0.18 (0.02-1.39)  0.10 
Tumor size 
  0.14   0.085 
T2 1.66 (0.85-3.21)    1.94 (0.91-4.11)    
T3 NA   NA   
T4 NA   NA   
Proliferation (qRT-PCR) 4.12 (1.32-12.85)  0.0148 6.04 (1.55-23.55)  0.00959 
Ki67 (IHC) 0.99 (0.96-1.02)  0.48 0.99 (0.96-1.02)  0.46 
B. Node Positive Subjects 
Outcome Relapse free survival Disease specific survival 
 hazard ratio (95% CI) p-value hazard ratio (95% CI) p-value 
Age 0.99 (0.97-1.01)  0.4032 1.00 (0.98-1.02)  0.8607 
Grade (1-2 vs 3) 1.08 (0.78-1.49)  0.64 1.24 (0.87-1.78)  0.23 
LVI 1.15 (0.80-1.65)  0.44 1.08 (0.73-1.60)  0.71 
HER2 (IHC)  1.67 (1.02-2.74)  0.40 1.89 (1.12-3.16)  0.02 
Tumor size 
  <0.0001   <0.0001 
T2 1.45 (1.04-2.02)    1.53 (1.06-2.22)    
T3 4.66 (2.42-9.00)    4.62 (2.22-9.60)    
T4 3.00 (1.52-5.96)    3.33 (1.65-6.73)    
Proliferation (qRT-PCR) 2.64 (1.50-4.62)  0.0007 3.04 (1.61-5.72)  0.0006 
Ki67 (IHC) 0.99 (0.97-1.01)  0.20 0.98 (0.96-1.01)  0.14 
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FIGURES 
 
 
Figure 1. Accuracy estimates from cross-validation of pathological models in the 
training set. The C-index was calculated during each of 100 rounds of cross-
validation from the "left-out" node negative samples. The bar height represents the 
mean C-index and corresponding standard error.  
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Figure 2 : Kaplan-Meier survival analysis of intrinsic subtype (panels A and B) and Risk 
of Relapse score (ROR-S, panels C and D), as determined by PAM50 gene expression 
measurement by qRT-PCR performed on paraffin blocks from women with invasive 
breast carcinoma, treated with adjuvant tamoxifen. The number of events and total 
number of patients in each group is shown beside each curve’s description. RFS = 
relapse-free survival (panels A and C). DSS = breast cancer disease-specific survival 
(panels B and D ; excludes two cases with unknown cause of death).  
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Figure 3: C-index estimates of relapse free (RFS) and disease-specific (DSS) survival for 
different measures of hormone receptors and proliferation. DCC = dextran-coated ligand 
binding assay. IHC = % positive nuclei by immunohistochemistry. The Luminal and 
Proliferation measures are the means of normalized qRT-PCR values across 8 and 11 
signature genes respectively, as described in Supplementary Methods. P-values were 
estimated from 1000 bootstrap samples. Single asterisk (*) designates significant 
improvement (p < 0.05) in C-index relative to clinical quantitative ER by dextrancharcoal 
coated ligand binding assay (DCC). Double asterisk (**) designates significant 
improvement (p < 0.05) in C-index relative to visual quantitative Ki67 index.  
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Figure 4: Comparison of prognostic classifiers in node negative subjects. The C-index is 
used to compare accuracy of the prognostic classifiers (panel A and Supplemental Table 
S5). * designates significant improvement (p < 0.05) in C-index relative to the clinical 
model (Adjuvant!) and ** to the IHC-T model. Taking the best-performing model, ROR-
PT values are related to actual 10 year event probabilities using a Cox proportional 
hazard model (panel B, dotted lines are 95% CI). Kaplan-Meier survival analysis of the 
size and proliferation weighted Risk of Relapse (ROR-PT) assignments are presented in 
panels C and D, and comparable information provided by a model of IHC subtype and 
tumor size is shown in panels E and F. RFS = relapse-free survival. DSS = breast cancer 
disease-specific survival (excludes two cases with unknown cause of death)  
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Figure 5: Comparison of prognostic classifiers in node positive subjects. A) C-index 
comparison of the accuracy of prognostic classifiers as described in Figure 3. B) Cox 
proportional hazard model relating the best performing model (ROR-T) to actual 10 year 
event probabilities. C) Kaplan-Meier survival analysis of the size weighted Risk of 
Relapse (ROR-T) assignments for RFS and (in panel D) DFS. E) and F) comparable 
information as provided by a model of IHC subtype and tumor size. 
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CHAPTER 4 
PROGNOSITIC UTILITY OF DNA COPY NUMBER ABBERATIONS IN BREAST 
CANCER 
 
Purpose: To expand our knowledge of breast cancer prognosis by determining the 
potential of a risk model that incorporates measures of DNA copy number aberrations 
Methods: A total of 1134 samples were curated from public sources, 
homogeneously annotated, and summarized using previously defined regions of copy 
number aberrations. Using overall survival as the outcome, a Monte-Carlo cross-
validation strategy was performed to compare three statistical learning techniques. A 
single model is carried forward for each of three clinically relevant strata – all patients, 
ER-positive patients, and luminal patients. These models are evaluated in two validation 
sets and compared to well known prognostic variables with multivariable regression. 
Results: The Elastic Net algorithm demonstrates superior performance of the 
models considered in cross-validation studies.  Models of DNA copy number aberrations 
constructed from heterogeneous platforms are successful as predictors of prognosis in 
two independent datasets for all patients or ER-positive and luminal cohorts, but not in 
ER-negative disease.  Predictions from the fixed models are significant after conditioning 
on available clinical data, and the luminal CNA based model is demonstrated to be more 
informative for prognosis than the luminal A versus B gene expression-based 
classification.
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Conclusions:  Copy number aberrations prove to be capable of robust prognostic 
classification and contribute information that is independent of available clinical factors. 
  

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INTRODUCTION 
A decade of research in the transcriptome of breast cancer has resulted in 
numerous findings of biological and clinical significance.  Microarray based 
measurement of the breast cancer transcriptome allowed identification of distinct tumor 
subtypes that are highly reproducible [1, 2], diverge in their prognosis [3, 4], and differ in 
their response to therapy [5, 6]. Gene expression patterns that define these subtypes are 
now well characterized, which has also lead to development of a diagnostic to provide 
valuable information to clinicians [7]. The clinical implications of gene expression 
subtypes are continuing to grow with new findings in neoadjuvant studies of taxane based 
regimens [8] and endocrine therapy [9].   
 Advancement of our biological understanding and the clinical utility of the breast 
cancer genomic DNA has lagged relative to these accomplishments from transcriptome 
studies. However, somatic mutations and copy number aberrations are known to be the 
causative factors for cancer formation and progression [10, 11]. Thus their identification 
and inclusion into diagnostics should allow for improved predictors and the identification 
of novel therapeutic targets.  
 Microarray based comparative genomic hybridization (aCGH) has been used to 
characterize Copy Number Aberrations (CNAs), their relationship to gene expression 
phenotypes, and their association with prognosis [12-20].  The work of Russness et al. 
[17] develops an objective CNA based classification system to characterize complex 
rearrangements and whole arm aberrations.  The classification system provides 
independent prognostic information compared to current clinical data and is associated 
with gene expression based subtypes.  A related study by Jonsson et al. [15] focused on 
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identifying specific copy number aberrations to drive their classification.  They find 
strong association between CNAs and gene expression subtypes.  Both studies identify 
expression subtype and prognostic associations with DNA amplifications in 8p, 11q, and 
17q. 
These studies provide substantial information on recurrent CNAs and the 
prognostic ability of CNA profiles.  These lead to the hypothesis that a supervised model 
of CNAs may provide increased prognostic ability in breast cancer. In support of this 
goal we have collected SNP microarray/CNA data and mRNA gene expression data from 
breast tumors of more than 200 subjects. Combined with 954 aCGH samples from the 
public domain [15, 17] we look to identify DNA copy number determinants of prognosis 
and determine if these additional markers add to the clinical utility of our existing 
predictive algorithms. This work illustrates an initial evaluation of supervised prognostic 
model development from CNA profiles. 
METHODS 
 Sample collection and data generation. 77 USA and 103 Norway (NW) samples 
that had blood/normal and tumor DNA pairs were analyzed using the Infinium Human-1 
109K BeadChip (Illumina, San Diego, CA, USA), with an average resolution of 1 probe 
per 26kb (median of 1 probe per 13kb).  Each sample was subjected to whole genome 
amplification (WGA), according to the Illumina protocol. 250 ng of genomic DNA was 
used as the WGA template (Gunderson, Steemers et al. 2005), and following 
amplification, the DNA was enzymatically fragmented, precipitated, and resuspended in 
Illumina resuspension buffer. Samples were then hybridized onto the Human-1 array 
overnight for 16h at 48°C. Post-hybridization, the beadchips were submerged in 
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hybridization buffer, spun dry in a centrifuge, and assembled into a TeFlow hydro-
chamber heated to 44°C. Using Illumina reagents, the ASPE (allele-specific primer 
extension) reaction and staining of the beadchips were performed. TeFlow chambers 
were then unmounted, and the beadchips were washed in wash buffer, and spun dry in a 
centrifuge. Within three days, beadchips were imaged on the BeadArray reader using 
BeadScan software.  To account for germline specific copy number polymorphisms, a 
pool of 118 blood-drawn DNA samples was compiled and used as Illumina’s standard 
clustering reference through the BeadStudio software, which estimates allele-specific 
intensity boundaries.  Genotype reports and LogR values were extracted with reference to 
dbSNP's (build 125) forward allele orientation using BeadStudio (v3.1, Illumina, San 
Diego, Ca, USA).  Sample information is in Supplemental Table 1 and LogR (A+B 
signal) values can be found on GEO under series GSE10893, platform GPL8139.  
 Collection of public aCGH data. A total of 595 aCGH tumors were previously 
combined by Russness et al. [17].  Raw data for 595 tumors was downloaded from 
http://www.ifi.uio.no.libproxy.lib.unc.edu/forskning/grupper/bioinf/Projects/GenomeArc
hitecture/.  Normalized gene expression and aCGH for an additional 359 tumors 
described by Jonsson et al. [15] were downloaded from the Gene Expression Omnibus 
(GSE22133). Probes for all arrays were assigned to genomic coordinates as defined by 
the GEO records for these platforms. All aCGH samples were mean centered. Gene 
expression subtypes were assigned to the set of 359 tumors after median centering of 
probes using the algorithm described in Parker et al. [7] and claudin-low samples were 
identified using the algorithm of Prat et al. [21]. 

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 Definition of copy number aberrations. The platforms used for aCGH varied 
greatly in this study. Assignment of uniform content across all samples was desired to 
facilitate efficient processing and interpretation. Recurrent copy number aberrations were 
previously identified across a diverse set of over three thousand tumors [22]. This work 
identified significant recurrent CNAs across all assayed tumors, and within each tissue.  
The CNAs identified from the overall analysis and the breast specific analysis were 
downloaded and defined by start and end genomic coordinate.  An additional set of breast 
cancer specific CNAs identified in Chao et al. [23] and the coordinates of each 
chromosome arm were included to create a total of 574 CNAs for further evaluation.  
Probes on each platform were mapped to these CNA regions and values for each sample 
were summarized by the mean (with or without scaling of probe variance) and the 
median.  Principle component analysis was performed to evaluation variation of the 
summarized CNA data across all cohorts. 
 Construction of prognostic models. The summarized CNAs were evaluated with 
Elastic-Net [24],  Least Absolute Shrinkage and Selection Operator (LASSO)[25], or 
simple linear regression, and a Cox proportional hazards model to build prognostic 
models. The LASSO uses an L1 penalty to generate models that are more interpretable 
due to the inherent variable selection. LASSO regression will often selects a single 
representative member to have non-zero weight among correlated predictors and the total 
number of selected variables may not exceed the number of observations. These issues 
motivated Zou and Hastie [24] to propose the Elastic Net, which selects multiple 
members from correlated groups of predictors, and demonstrates improved performance 
when the number variables is much greater than the number of samples. A third strategy, 
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termed Nearest Template Prediction (NTP) [26], collects the statistics from univariable 
models of N genes to be used as coefficients in a linear predictor. 
Data from the UNC (n=77), Norway (n=103), and Jonsson et al. (n=359) were 
stratified into a combined training set (n=349) stratified by data source and ER status. 
The remaining samples (n=190) formed the initial test set. The complete Russnes et al. 
cohort (n=595) was broken into 470 subjects that are independent of the training and test 
sets and are used as a validation set. The remaining subset of Russnes et al. is the same 
subjects assayed in Norway cohort; because these are the same subjects on a different 
platform, they are not useful for clinical evaluation of a classifier, but are valuable to 
understand cross-platform performance. This set is referred to as the ‘platform training 
set’.   
Monte-Carlo cross-validation [27] (200 iterations of 1/3 train and 2/3 test) was 
performed within the training set (n=349) to optimize algorithm specific parameters.  The 
optimized algorithm was used to fit a model to the entire training set.  This model was 
then used to evaluate the test set (n=190) and the independent validation set of 470 
tumors from Russnes et al. A diagram of this process is illustrated in Figure 1. The entire 
process of training and testing was repeated after limiting to only ER+ or ER- samples in 
all cohorts. 
Prognostic models were evaluated using a Cox proportional hazards model, 
estimation of the C-index, and Kaplan-Meier analysis of categorized values. The Cox 
proportional hazard model provides a test of significance for the model assignments in 
the test sets. The prognostic ability of the models and known prognostic predictors was 
further characterized by calculating the concordance index (C-index) [28]. The C-index is 
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a measure of the probability that, given two randomly selected patients, the patient with 
the worse outcome is, in fact, predicted to have a worse outcome. This measure is similar 
to an area under the receiver operating characteristic curve, ranging from 0.5 to 1. For 
each cohort, we used the model built from the training set to calculate the C-index of the 
testing set. The Kaplan-Meier analyses, patients were stratified into high and low-risk 
groups based on their respective risk score, which was defined as the natural logarithm of 
the hazard ratio with a chosen cut-off value for stratification into high and low-risk 
groups of zero. Significant association of the two groups with overall survival was tested 
with the log rank test. 
GLOBAL CHARACTERIZATION OF RECURRENT COPY NUMBER 
ABERRATIONS IN BREAST CANCER  
Development and robust evaluation of novel prognostic models requires a large 
collection of samples so that training and testing can be adequately addressed. A total of 
1134 samples were collected from three recent publications [15, 17, 23]. The robustness 
of a model can be limited by the data used to estimate model parameters.  Thus, it is of 
interest to evaluate if the sample is representative of the general population.  As our 
sample diverges from the population the potential for general inference diminishes.  The 
potential for a biased sample, or for bias between training and testing sets is reasonable 
given that the samples were generated from six different studies and are heterogeneously 
treated. The presence of bias can be investigated by analysis of expected prognostic 
variables. Kaplan-Meier plots associating levels of estrogen receptor (ER) status, tumor 
size, node status, grade, and cohort with overall survival are shown in Figure 2.  Results 
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indicate expected associations for all clinical factors which provides some evidence that 
the combined sample is from a representative population.   
These results also indicate the potential for cohort bias is the UNC109k data set, 
which has generally worse prognosis that the other cohorts.  To account for this effect, 
subjects in the Chao et al. and Jonsson et al. studies were randomly assigned to the 
training (2/3 of subjects) or testing (1/3 of subjects) cohorts after stratification by ER 
status, grade, and cohort. The Russnes et al. cohort included 103 subjects also present in 
the Chao et al. cohort and these form the ‘platform test set’ used for evaluating classifier 
reproducibility, but not evaluated for clinical performance.  The remaining 470 samples 
of Russnes et al. are used as a second independent test set, termed the ‘validation’ set.  
The clinical and pathologic characteristics of the breast cancer patients from these 
four cohorts are described in Table 1. The typical patient in these data displayed ER-
positive (61%) , HER2-negative (79%), and node –negative (53%) disease.  The median 
follow-up of this population was 8.2 years with median survival of  12 years. Tumor size, 
ER status, PR status, node status, gene expression subtype, and grade were prognostic 
(Figure 2) confirming that the combined dataset shows the expected outcomes for known 
biomarkers. No statistically significant differences for outcome were observed across the 
four datasets that were combined. 
The diverse aCGH and SNP platforms represented by the combined cohort 
required mapping to a uniform set of variables for effective processing and interpretation.  
Known sites of recurrent CNAs defined in previous publications [22, 23] defined 574 
regions of the genome.  DNA probes were from each array were mapped to these regions 
and summarized to a single value for all probes in the region.  Summarizations occurred 
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by calculating the sample median or mean to create two data sets.  Probes were allowed 
to participate in multiple regions when the CNA definitions overlapped.  Principal 
component analysis of the mean summarized data is illustrated in Figure 3.   Variation in 
the top components is not associated with the published cohorts, but does segregate 
samples by their gene expression based subtype.  Separation in the top component of 
variation isolates basal-like samples from other tumors indicating the possibility of 
substantial shared CNA content that is exclusive to the basal-like subtype. 
MODEL SELECTION 
 Segregation of gene expression subtypes by CNA profiles provides initial 
evidence that robust prognostic information is available in these data.  In addition, 
amplifications in 8p, 11q, and 17q have been associated with poor prognosis in 
independent studies.  These results point to the potential for a prognostic model of 
individual CNAs.  A supervised model may identify additional recurrent CNAs and 
provide independent prognostic information relative to current standards.  This goal 
requires a modeling strategy that includes feature selection and is capable of learning 
with censored survival outcomes. Three candidate algorithms were selected based on 
these requirements.   
The LASSO, Elastic net, and NTP algorithms were evaluated with Monte-Carlo 
cross-validation (MCCV) within the training set.  The parameters for each model were 
varied to generate different sized gene sets contributing to each model. A total of 200 
MCCV iterations were performed for each combination of parameter and model, with 2/3 
of samples assigned to the CV training set and 1/3 assigned to the CV test set in each 
iteration.  Accuracy relative to  overall survival was measured with the C-index and was 
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calculated in the CV test set.  Parameter values for each method may greatly vary, but all 
result in varying the number of CNAs which contribute to the model. Loess regression 
summarizes the C-index estimates relative to the number of CNAs with non-zero weights 
for each algorithm Figure 4A-C.  The optimal values of all models are similar; however, 
NTP requires many more CNAs to reach the maximum C-index.  Elastic Net and LASSO 
were more similar in performance, but Elastic Net estimates appear more stable than 
those of LASSO. 
A subset of 103 subjects present in Russnes et al. were independently assayed and 
included in the Norway cohort.  These samples were separated so that the remaining 
Russnes et al. samples form a independent validation set.  However, these samples still 
contain value for assessing the ability of each combination of model and parameter to 
provide robust predictions across the heterogeneous platforms.  Results from MCCV 
indicate that the Elastic Net and LASSO algorithms demonstrate improved performance 
relative to the NTP algorithm in this regard (Figure 4D-F).  These results motivated 
selection of the Elastic Net algorithm and associated parameters to be carried forward. 
PROGNOSTIC PERFORMANCE OF CNA MODELS 
Prognostic models were constructed using the training set optimized parameters, 
and then applied to the test and validation cohorts. Initial evaluation of the assigned 
scores was performed after categorizing samples as low risk or high risk based on 
comparison to the median score among training cases. This two group classification was 
significantly associated with survival in all patients (Figure 5A-B), and patients with ER-
positive tumors (Figure 5C-D), but not ER-negative disease (data not shown); cross-
validation results in ER-negative tumors did not consistently produce prognostic models 
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with C-index greater than 50%.  C-index estimates of the continuous values were also 
significantly above 0.5 in all tumors [train set: 0.65 (95% CI: 0.58-0.71); validation set: 
0.59 (95% CI: 0.55-0.63)] and in the ER-positive cohort [train set: 0.62 (95% CI: 0.53-
0.72); validation set: 0.61 (95% CI: 0.56-0.66)]. Samples were also stratified by gene 
expression subtype to form a luminal (luminal A or luminal B combined by the PAM50 
classifier) division of the training and test sets. Similar significant outcome predictions 
were also obtained for the cohort of patients defined as having luminal tumors. 
Model assignments were evaluated further with likelihood ratio tests of the null 
hypothesis that the CNA risk scores do not add significant explanatory power. Cox 
proportional hazard models of available clinical factors were constructed with and 
without the CNA risk score.  Tests were performed using the assignments as continuous 
values or as two groups. Results of these tests in both the test and validation sets are 
shown in Table 3.  The results indicate that the CNA risk score provides significant 
prognostic information as a continuous predictor when evaluating all cases or within ER-
positive tumors after accounting for available clinical variables.  Interestingly, the CNA 
risk score is significant even after accounting for variation described by the CNA 
classification system proposed in Russnes et al.  Results from the two group encoding are 
similar, although the CNA risk scores are only borderline significant when accounting for 
the Russnes et al. classification.  
The luminal specific CNA model is significantly associated with overall survival 
in the test set when used as a continuous predictor (p=0.0017) or when split into two 
groups (HR=3.1; p=0.00022). Multivariable analysis in the luminal test set was 
performed to determine if the luminal CNA classifier explains significant variation in 
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prognosis after conditioning on the luminal A or B classification.  This test indicated that 
the luminal CNA model was a significant predictor when used as a continuous variable 
(p=0.031) or when dichotomized (HR=2.7; p=0.015).  Further, the luminal A vs. B 
classification was no longer a significant predictor (p=0.33) after conditioning on the 
luminal CNA model predictions.  
CNAs SELECTED FOR PROGNOSTIC MODELS 
An important aspect of these CNA derived risk models is the potential for the 
selected regions to identify causative genes. In order to robustly identify prognostic 
variables, 200 rounds of cross-validation were used to optimize feature selection 
parameters. Selection resulted in 76 CNAs contributing information to the model of all 
samples, and 51 CNAs in the model of ER-positive samples. Examination of the selected 
modules for the complete and ER-positive cohorts revealed substantial overlap (49 CNAs 
in common). Among the selected CNAs for the model of all breast tumors, 21 were 
identified as recurrent aberrations across numerous tumor types, 50 were identified as 
recurrent aberrations in breast cancer, and 5 represented chromosome arms alterations.  
CNAs with positive weights (amplification is associated with worse prognosis) were 
slightly less frequent in the model (47% of selected CNAs).  The model of ER-positive 
disease indicated similar results with 13 CNA that were identified as generally recurrent 
in cancer, 35 were breast cancer specific, and 3 represented whole chromosome arms. 
These frequencies represent equal proportion of representation from each category.  An 
annotated list of CNAs found in each model and their corresponding weights are 
provided in tables 4 (negative weights) and 5 (positive weights). 
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Selected CNAs were composed of significantly more annotated genes (mean = 
24) than unselected segments (mean = 13;  t-test p = 0.034)  while displaying practically 
identical size distributions (median size of 1.30Mb for selected CNAs and 1.31Mb for 
unselected). Annotation of these gene lists was performed by comparison to the mSigdb 
collection of published gene signatures.  Significant enrichment (p<1e-10 with the 
compute overlaps tool) was observed for gene lists corresponding to multiple previously 
characterized amplicons in glioma, pancreatic, and neuoendocrine cancers. After limiting 
to curated pathways, significant overlap was identified with genes in the PI3K pathway 
and cell-cell junctions. The selected regions were further analyzed with the GRAIL 
algorithm [29].  This method identified “kinase” as the top literature search term 
associated with CNAs in both models providing independent support for enrichment of 
cell signaling pathways in these prognostic models. 
COMPARISON OF CNA AND GENE EXPRESSION BASED MODELS 
Gene expression data have been extensively evaluated for prognostic utility in 
breast cancer.  The CNA derived risk models developed here have demonstrated 
prognostic ability, but this must be compared to gene expression based models to 
establish relevance.  The same cross-validation strategy and Elastic Net algorithm was 
used to construct models of the gene expression data, the CNA data, or a combination.  
Performance evaluation in the test set allows direct comparison of the prognostic 
information content available in each data type. 
A total of 323 different gene expression signatures/modules [30] were estimated 
from the combined dataset. Cross-validation with the gene expression modules results in 
higher C-index estimates across a wide range of parameters for either all patients or ER-
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positive samples (Figure 6).  Performance of learning from the combination of both data 
types does not appear to increase accuracy relative to the gene expression models alone.  
Evaluation in the test set confirms these results.  Specifically, the C-index estimates of 
the gene expression based models are significantly greater than the CNA derived models 
(p<0.05, empirical p-value from bootstrapped differences), and the combined models are 
not a significant improvement over the gene expression based models. While these results 
suggest limited clinical impact of the CNA based models, a negative result in this 
scenario of combined cohorts and protocols must be interpreted with caution.  
DISCUSSION 
Genome-wide gene expression data have provided a wealth of information on the 
underlying diversity of breast cancer.  This information has been useful for understanding 
prognostic outcomes and other clinical correlates.  The correlations between CNAs and 
gene expression, along with the likely causative role of CNAs, give great potential insight 
from investigation of CNA profiles. This has led multiple groups to report biological and 
clinical associations with CNAs from genome wide measurement. The work presented 
here expands on the prognostic associations using extensive independent validation of a 
fixed predictor to provide a robust characterization of the relationship between CNA 
profiles and overall survival.   
The potential for a CNA based model was first demonstrated by the common 
findings in recent related publications [15, 17]. These results demonstrate clear 
correlations between gene expression based subtype and either genome wide CNA 
profiles or specific CNAs.  After combining these heterogeneous data sets totaling 1134 
samples, we find that PCA of genome wide CNAs easily segregates basal-like samples 
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from all others, and provides some segregation of the remaining subtypes. The 
segregation is independent of data source, indicating that a common set of CNAs are 
involved in the gene expression subtype associations described in previous work.  
The gene expression subtypes are established prognostic factors, thus it was 
hypothesized that CNAs may carry some of this prognostic information.  We chose to test 
this hypothesis through the construction and evaluation of a prognostic model based on 
CNA profiles. A model was fit to the entire training cohort and used to evaluate an 
independent set of samples collected in the same fashion as the training set (‘test set’), 
and a second independent set (‘validation set’) which was collected and assayed by 
different methods, but recently combined for a related study [15]. Due to the 
heterogeneity of cohorts and platforms, estimates in the test and validation sets may 
under estimate the performance of a CNA model constructed and evaluated in the 
absence of these technical factors.  This also means that a negative result would not 
provide strong evidence that CNA profiles are not capable of robust prognostic 
information.  In contrast, positive results indicate the potential for a CNA based 
prognostic model, and provide candidate CNAs for further biological study. 
 Three methods – NTP, LASSO, and Elastic Net – were chosen as candidate 
strategies for model construction due to their properties of feature selection and the 
ability to learn from censored survival data. Cross-validation was used to evaluate the 
methods and associated parameters, which led to the selection of the Elastic Net 
algorithm. The maximum CV accuracy of Elastic Net was similar to the other methods; 
however, the Elastic Net was more robust to cohort and platform bias, demonstrated 
optimal performance with a reduced feature set, and generated stable performance 
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estimates over the range of optimization parameters.  Selection of Elastic Net fits with the 
work of Zou et al. [24] where the performance of Elastic Net is demonstrated to be 
superior when the number of variables is greater than the number of samples.  This is true 
of the training set in this study.  
Breast cancer genomics have demonstrated utility in prognostic classification 
beyond what can be inferred from pathological evaluation.  Multiple prognostic 
expression profiles have been identified using diverse populations and methods.  These 
signatures consist of different gene sets, but are generally concordant in their prognostic 
information content [31], indicating that most are describing the same disease progression 
process. This scenario provides two opportunities for determining the clinical 
implications of tumor DNA.  The tumor DNA may harbor variation that is prognostic, but 
concordant with current clinical and expression based classifications. In this case, the 
results from previous work may be re-evaluated to examine the prognostic locus more 
closely and identify the causative pathway. A second possibility is that variation in tumor 
DNA describes prognostic variation not otherwise explained by expression or other 
clinical parameters. Here the predictive ability of the novel locus was be evaluated in 
detail to understand the context in which it is informative. 
General performance of the models is similar to results from gene expression 
studies where successful prognostic models have been repeatedly identified in ER-
positive cohorts, but to a much lower extent in ER-negative cohorts. The luminal A vs. B 
classification is one example of a robust gene expression based marker in generally ER-
positive cohorts.  Here we provide evidence that CNA profiles mimic the prognostic 
information of this classification and may explain a larger magnitude of prognostic 
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variation.  The luminal A vs. B classification, as with most ER-positive prognostic 
models, is driven by expression of proliferation markers. Thus, the identified CNAs may 
point to a set causative factors underlying the enhanced proliferation of these tumors.  
Support for this hypothesis is strengthened by the abundance of kinase genes in these 
regions. 
Elastic Net models constructed from all samples, or ER-positive samples, were 
highly similar in content and both were successful.  The concordance remains high if the 
same number of segments is chosen for both models. Further, the inability to identify a 
successful model in ER-negative samples indicates that models from the complete cohort 
and the ER-positive cohort are driven by the same signals in the training set. The 51 
CNAs that are identified in the ER-positive model represent 29 unique regions of the 
genome that range in length from 80kb to whole chromosome arms. The redundancy is 
expected with the Elastic Net algorithm and is likely a key factor to ensure consistent 
performance across platforms. Heatmaps illustrating high correlation between selected 
CNAs are due to overlapping CNAs, or those in close proximity in the genome.  
Correlation between CNAs from different chromosome arms is observed in these data as 
reported previously [17], but the set of selected CNAs does not include any segments 
from different chromosome arms with high correlation (r > 0.4) between them.  
A comparison of CNA and gene expression based models resulted in superior 
performance of the RNA models, although successful CNA models could be built.  
Further, the combination of variables did not improve on gene expression alone.  This 
result should be interpreted with caution as numerous studies have generated incremental 
improvements in normalization and data summarization steps for across platform gene 
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expression studies.  In contrast, the equivalent steps used here for cross-platform CNA 
analysis are not as well characterized.  In addition, gene expression measurements by 
microarray demonstrate a much larger dynamic range than is typically expected for 
CNAs. This difference may render comparison of CNA estimates across platforms more 
problematic than gene expression.  
Another important caveat of these analysds concerns selection of the Elastic Net 
parameters. Optimization of the Elastic Net parameters was performed during cross-
validation of the training set.  However, these may not provide global optimum values for 
prediction onto the test set.  A retrospective analysis was performed to explore the upper 
bound of performance in this experiment.  Models were constructed in the training set 
using a diverse set of parameters, and all models were evaluated in the test set.  C-index 
estimates in the test set indicate that the optimal number of CNAs may have been 
underestimated for the prospective models characterized in previous sections.  The 
models of all patients, or ER-positive alone, demonstrate optimum performance in the 
test set when parameters cause selection of approximately 140 CNAs.  This increase in 
selected CNAs would have improved the test set C-index estimate by 1% for all samples 
and 4% for the ER-positive cohort. These models are not presented due to the increased 
likelihood for overly optimistic results.   
The CNA models developed here were constructed and evaluated with robust 
methods using data from multiple cohorts and diverse platforms.  This scenario may 
result in reduced potential, but allows conservative estimation of CNA based model 
performance and greatly reduced likelihood for chance selection of prognostic CNAs. 
Thus, the analysis presented here provides two valuable results – identification of specific 

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CNAs which contribute to prognosis, and an initial evaluation of a supervised prognostic 
model based on CNAs, both of which yielded promising results.  
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

TABLES 
Table 1. Clinical characteristics of each published cohort. 
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Table 2. Clinical characteristics of each cohort used for analysis. 
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Table 3. Multivariable analysis results of the CNA model predictions in the Test and 
Validation sets.  The “Continuous CAN RS” represents the linear predictions of the 
Elastic Net model. The “Two group CNA RS” variable was based on comparison of 
predicted value to the median fitted value of the training set.  Hazard ratios were 
estimated from a Cox model including the listed “Conditioning Variables” as additive 
terms.  The p-values are from likelihood ratio tests of Cox models with and without the 
CNA model assigned feature.
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Table 4. Annotation of features and their coefficients from the two successful models. 
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Table 4 continued. 
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Figure 1. Cross-validation and test
et al. cohorts were combined then randomly assigned to the training set or test set after 
stratification by grade, ER status, and cohort (1).  A fourth cohort from Russnes et al. was 
reduced to a set of 470 independent 
then repeatedly randomized into CV train and CV test sets (2) to optimize model 
parameters.  A subset of 104 Russnes et al. samples were also assayed in the MicMa109k 
set.  These samples form the CV Pla
performance during CV.  Selection of model parameters was performed based on 
performance (C-index) in the CV Test and CV Platform Test sets.  Selected parameters 
were used to build a model from the comple
Validation sets. 
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ing strategy.  The UNC109k, MicMa109k and Jonssen 
samples as the validation set.  Training samples were 
tform Test set used only to evaluate cross
te Train set and evaluated in the Test and 
 
-platform 
Figure 2. Kaplan-Meyer plots of relevant variables from the combined data set.
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Figure 3. Principal component analysis of the combined cohort after summarization to the 
mean within each copy number aberration.  The top two components of variation do not 
stratify by cohort (left) but demonstrate segregation by gene expression based subtype 
(right). 
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Figure 4. Performance of models and parameters during cross-validation.  Two hundred 
iterations of each parameter setting for each of the three models were performed.  The C-
index was calculated from the test set of each iteration.  The relationship between number 
of selected segments (CNAs) and C-index is summarized with loess curves.  Line color 
indicates the segment summarization method (probe with max IQR = black, mean of 
probes = blue, mean of scaled probes = red).  The top row is performance of three 
modeling algorithms in the CV Test sets and bottom row is performance in the CV 
Platform Test sets. 
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Figure 5. Kaplan-Meyer plots of predictions in the Test (left) and Validation (right) sets 
for all samples (top) and ER-positive samples (bottom).  The model that generated these 
predictions was built from the complete training set and used parameters that generated 
76 contributing segments for the all samples model and 51 contributing segments for the 
ER-positive model.  Predicted values were stratified into low or high risk by the median 
of fitted values in the training set. 
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Figure 6. Performance by feature type with Elastic Net  (top and middle rows). Two 
hundred iterations of each parameter setting for each of the three models were performed.  
The C-index was calculated from the test set during each iteration.  Gray points are 
individual C-index estimates from each round. The relationship between number of 
selected segments (CNAs) and C
lines represent the number of features selected for the final model.  (bottom row) Test set 
performance of the final model by feature type.  Error bars indicated 95% confidence 
intervals from bootstrap sampling of the test set.
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CHAPTER 5 
CONCLUSION 
 
High throughput technologies allowing parallel measurement of genome wide 
gene expression and DNA copy number events have generated a wealth of data for 
stratification of tumor samples.  These gene expression measures in breast cancer have 
demonstrated repeatable correlated patterns that stratify samples into clinically 
meaningful groups.  Results of these studies laid the foundation for construction of the 
PAM50 classifier.    
The PAM50 assay is a centroid based classifier consisting of 50 gene expression 
measurements by qRT-PCR and/or by microarray. The qRT-PCR platform was chosen as 
it is currently used for clinical testing, and was further optimized for old age FFPE tissue. 
This potential was necessary to gain information from retrospective cohorts including 
randomized clinical trials. Primers for 160 genes had been optimized for tissues of this 
type (i.e. FFPE), and over 200 samples were available that had been assayed by all 160 
primers and by microarrays.  These data were essential for translating the information 
from microarrays to the qRT-PCR platform. 
Cluster analysis of the microarrays was analyzed with the SigClust algorithm to 
define reproducible subgroups of samples.  Four of these subgroups represented the 
previously characterized subtypes, and a set of true normal samples were used to define 

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the normal-like class.  Together, these five groups of samples represent the gold standard 
samples for each subtype.  Cross-validation analysis was performed with the qRT-PCR 
version of these samples to identify the centroid classifer and 50 genes that provided 
robust classification.
The clinical importance of the classifier is not only the subtype call, but the 
prognostic and predictive information that are inferred.  The subtype information was 
optimized for prognostic classification with a Cox proportional hazard model to relate 
classifier assigned subtype distance measures and relapse free survival. This risk of 
relapse (ROR) model was fit with ridge regression to provide robust weights for each 
term. Multivariable analysis indicated that scores resulting from this model are significant 
prognostic indicators and replace historic markers for ER and PgR.  However, 
multivariable analysis also indicated that clinical information such as tumor size is still 
very informative, thus, the modeling strategy was extended to construct models that 
included clinical information as well.   
Initial evaluation of this combined genomic and clinical model demonstrated 
significant improvement in prognostic classification relative to current clinical markers or 
genomics alone. The first large scale evaluation of the 50 gene assay consisted of 711 
ER+ samples treated with endocrine therapy.  Results indicate that the prognostic models 
are more informative than either current clinical standard or previously proposed 
immunohistochemical (IHC) subtype definitions.  Most importantly, the PAM50 test is 
capable of identifying a subset of node-negative subjects that have a very good long term 
prognosis with 5 years of tamoxifen treatment alone. 
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A second goal of the gene expression assay is to predict the best therapeutic 
option for each patient. As a first evaluation, a dataset combining three cohorts of similar 
treatment with taxane based chemotherapy, totaling 357 samples, was collected and 
subtyped using the 50 gene classifier. These neoadjuvant studies contain pathologic 
complete response (pCR) as the primary outcome. Pathologic complete response is 
defined as the complete lack of residual tumor upon inspection by a pathologist after 2-3 
months of treatment  The presence of residual disease is the complementary value for this 
binary variable, with a pCR portending good long term survival. 
Multivariable analysis indicated that subtype alone contained independent 
predictive (i.e. benefit of administered therapy) information.  Further studies that focus 
on prediction of pCR with a logistic model carrying the same terms as for prognosis, and 
again fit with ridge regression have been initiated. Improving on results of pCR 
prediction with the ROR model, results from this model indicate that the subtype 
assignments provide increased accuracy when predicting benefit to taxane based multi-
agent chemotherapy. In addition, current clinical information does not appear to add pCR 
predictive information in the context of subtype.  
The first two studies show that genomics have demonstrated utility in prognostic 
and predictive classification beyond what can be inferred from pathological variables.  
Prognostic expression profiles have been identified in other studies using diverse 
populations and methods.  These signatures consist of different gene sets, but are 
generally concordant in their prognostic information content, indicating that most are 
describing the same disease progression process.   However, the information content of 
DNA may be more accurate or provide new information to gene expression based tests. 
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A handful of genetic determinants and their corresponding tumor phenotypes are 
known, however, the genetics of transformation and progression for most tumors remains 
unidentified. The likely causative role of DNA aberrations promotes evaluation of 
prognostic models constructed from DNA copy number aberrations.  Available data for 
this experiment have been assayed by numerous platforms at various sites.  This 
heterogeneity may compromise sensitivity of modeling important CNAs in the 
experiment, yet the global CNA profiles easily segregate the disease subtypes as 
determined by gene expression.   
A rigorous cross-validation strategy was utilized to ensure selection of robust 
features.  The resulting models demonstrate minimal bias as evident by similar 
performance estimates from cross-validation and on the test and validation data sets. 
Further evaluation demonstrates that the resulting models prove to be informative in ER-
positive disease, and may provide more prognostic information than the luminal A and B 
stratifications. A hypothesis stemming from this result is that the identified copy number 
aberrations may be driving variation in gene expression of cell cycle genes.  This is 
supported by the enrichment of signaling factors (kinases) and their receptors in the 
identified regions. Future studies should be conducted to more definitively test these 
associations and identify the potential oncogenes or tumor suppressor genes that are the 
driving carcinogenic events. 
Success of the CNA based models may be important for elucidating tumor 
biology, but does not greatly add to gene expression information in this data set.  This 
negative result must be interpreted with caution due to the heterogeneity of measurement 
technology, although it may be true that gene expression variation encompasses the 
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prognostic information content of CNAs.  If so, future studies should focus on CNAs 
associated with prognostic gene expression profiles to identify key genes involved in 
regulating these pathways. 
Variation in gene expression has proven to be a reliable and highly informative 
source of clinical information.  These data have now been translated to a meaningful 
clinical assay that has been validated in a relevant clinical cohort, and is being evaluated 
further in multiple clinical trial cohorts.  CNAs provide another source of variation that 
has great potential for clinical application and technology is becoming available to mimic 
these studies with other types of genomic, genetic, epigenetic, and metagenomic 
variation. The potential for these technologies must be robustly evaluated as performed 
here with CNA measures. Positive results should then be translated into clinically 
relevant assays as performed with the PAM50 classifier.  Continuation of this 
development cycle will provide ever increasing information for the management and 
treatment of patients afflicted breast cancer. 
 
 
